Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2)

EDITOR—We have previously reported on a large clinical study of patients with neurofibromatosis 2 (NF2) and described the usefulness of audiological screening in early detection of VS in NF2. Although DNA diagnosis is possible by linkage analysis and by detecting the NF2 family specific mutation, this is not possible in all cases. Only 40% of sporadic patients (new mutations) have an identifiable NF2 mutation and as 50% of NF2 patients have no family history, up to 30% of those at risk of NF2 will not be able to have a DNA presymptomatic test. While it is possible to calculate residual risks of NF2 from age at onset of symptoms curves, a more useful measure would be the level of risk reduction from a normal cranial MRI scan. A database recording information on affected subjects with NF2 was set up in Manchester in 1989. Patients were actively sought across the UK from paediatricians, neurosurgeons, ENT surgeons, geneticists, and dermatologists. We have used this database to determine the age at which MRI detects asymptomatic tumours in subjects with NF2 and the value of audiological screening. We have also created life curves for risk reduction in subjects at 50% risk of NF2.

Patient details from hospital notes and proforma have been entered into a database at St Mary’s Hospital Manchester since 1989. A total of 344 patients fulfilling our published criteria for NF2 are recorded (table 1), 1 3 5 Information on all known tumours, age at presentation and diagnosis, and many different symptoms are included. We have analysed details of patients who have been detected as having VS on a screening MRI scan without any known central nervous system pathology, signs, or symptoms. It has been our practice to carry out a baseline MRI scan between 12 and 16 years of age, although some centres have screened earlier. A review was also made of subjects diagnosed on the basis of presymptomatic DNA tests. A separate analysis was undertaken on those cases who had sequential audiological screening with pure tone audiogram and ABR before MRI scanning. Standard MRI screening usually involved T1 and T2 weighted images before, and T1 weighted images after gadolinium enhancement with 3 mm cuts through the internal auditory meati.

A cumulative age at onset curve was derived from the age at presymptomatic diagnosis on MRI scan (fig 1) and for residual risk of NF2 (fig 2). An adjustment was made for large tumours detected on initial prevalence scan. This allowed for an annual growth rate of 2 mm (derived from our unpublished data and those of M Baser/V Mautner) with a minimum detection size of 2-3 mm. Thus, a 20 mm tumour could have been detected up to an average of eight or nine years earlier. Age of onset curves were also derived from offspring in NF2 families to determine the proportion who had developed symptoms by each five year age group. Residual risks of NF2 were based on Bayesian calculations, so when 67% of subjects would be expected to be symptomatic or detected on MRI the residual risk of NF2 would be 25%.

MRI screening is useful for reducing the residual risk of someone at initial 50% risk of inheriting NF2. ABR screening still has a place in early detection of vestibular schwannoma, although MRI screening is the method of choice.

Forty three first degree relatives of NF2 patients have been diagnosed with NF2 presymptomatically. Twenty one patients were diagnosed initially with a presymptomatic DNA test using linkage or mutation analysis. Fourteen of these have subsequently been found to have VS on MRI scan. The remaining seven children have not had an initial MRI scan. Twenty one further patients were diagnosed on the basis of an MRI scan before having symptoms. These scans were carried out on initial assessment when the patient was first known to be at risk. Thus, some scans were only performed when the patients were in their twenties to forties and the tumour size at initial diagnosis therefore varied from 1-20 mm in diameter. Mean age at initial positive scan was 20.5 years (range 8-45 years, median 18

Table 1  Diagnostic criteria for NF2

<table>
<thead>
<tr>
<th>Bilateral vestibular schwannomas OR family history of NF2 PLUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Unilateral VS OR</td>
</tr>
<tr>
<td>(2) Any two of: meningioma, glioma, neurofibroma, schwannoma, posterior subcapsular lenticular opacities</td>
</tr>
<tr>
<td>Additional criteria</td>
</tr>
<tr>
<td>Unilateral VS + any two of: meningioma, glioma, neurofibroma, schwannoma, and posterior subcapsular opacities</td>
</tr>
<tr>
<td>OR</td>
</tr>
<tr>
<td>Multiple meningioma (2 or more) + unilateral VS or any 2 of: glioma, neurofibroma, schwannoma, and cataract</td>
</tr>
</tbody>
</table>

Figure 1  Cumulative chance of detecting NF2 using MRI based on prospective screening in 35 at risk subjects.

Figure 2  Residual risk of NF2 if MRI negative based on screening 35 at risk subjects.
All but two patients were the offspring of a known NF2 patient. One father of a severely affected NF2 patient who claimed not to have symptoms had bilateral 15 and 10 mm VS on initial MRI scan aged 45 years. A further 53 year old male with an affected brother has had a normal MRI scan, but his son aged 19 years had a unilateral VS on scan aged 19 years. The family have a deletion in the NF2 gene removing one exonic cosmid (J Dumanski, personal communication). Only three patients had an initial normal MRI scan. The 45 year old father noted above was excluded from analysis as he may represent a mosaic and not at a priori 50% risk. Of the 34 patients detected presymptomatically, DNA presymptomatic testing would be possible in 24 owing to the presence of a known mutation or a pedigree structure suitable for linkage analysis at time of diagnosis. However, in 10 cases (30%) no testing would have been possible if the patient presented at the time of writing. Age of onset of symptoms in 110 offspring of NF2 patients is presented in fig 3, 10% of NF2 offspring present symptomatically before 10 years of age. Our corrected curves assume an arbitrary rate of growth of 2 mm per year. Many of the families in which presymptomatic diagnosis was made are at the extreme mild end of the scale with missense or splice site mutations and large deletions. All the patients in table 2 in which a mutation had been found had these types of mutation. Nonetheless, faced with a patient without obvious features of NF2 in which the family history of NF2 is mild, the curves are very useful. Most patients with severe NF2 do not have children and therefore most offspring are at risk of the milder forms of the disease. Indeed, many children of sporadic patients with NF2 may be at less than 50% initial risk owing to gonosomal mosaicism in their parent.

The value of early detection of VS is still open to some debate. However, the only realistic chance of hearing preservation surgery is when the tumour is small and tumours may not present symptomatically until 20 mm in diameter. ABR testing, while not detecting some of the very small intracanalicular tumours, still detected the great majority of tumours at a size when hearing preservation surgery would not have been compromised. However, the larger size at detection would leave less leeway for observation of the growth rate of the tumour. Where MRI scans are not less accessible, ABR testing has more of a role than CT scanning (see case 11) and could serve as a back up to MRI in the interval years after normal scans.

It is clear that NF2 patients fare better if they are managed in specialist centres where surgery and occasionally other measures such as radiosurgery can be offered at the appropriate time. In experienced hands, hearing can be preserved with removal of VS and rehabilitation is now possible with auditory brain stem implants and on occasion with cochlear implants.

There is still clearly a place for MRI and audiological screening in at risk relatives as 30% of the patients in this study would not have been able to have predictive DNA tests. While the proportion of families with mutations can be boosted by a comprehensive deletion finding strategy, these are not widely available for NF2 or many other diseases (BRCA1/2) and still fail to detect mosaic
mutations. A child who presents with NF2 with no family history is likely to represent a new mutation of the NF2 gene. If there is no suggestive family history, the risk to parent and sibs is still low (probably <1%). The cases presented here of two parents being affected after a child is to our knowledge the first such report. There is also no objective evidence that VS disease is worse in females than males. All four of the female sibs in table 2 had smaller VS at initial scan than their male counterparts.

Children of affected patients should be considered to be at 50% risk of NF2 and screening for NF2 can start at birth.5 Cataracts can affect vision in early life and other tumour implications are present in the first 10 years of life. Formal screening for VS should start at 10 years, as it is rare for tumours to occur before that time. Audiological tests including ABR are still a useful adjunct to MRI and can determine severity of disease.

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Side</th>
<th>Age at MRI diagnosis (y)</th>
<th>Pure tone audio</th>
<th>ABR at MRI diagnosis</th>
<th>ABR 12 months later</th>
<th>Previous normal MRI (y)</th>
<th>Size of VS on MRI (mm)</th>
<th>Mutation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>Left</td>
<td>16.9</td>
<td>Normal</td>
<td>Normal</td>
<td>Abnormal</td>
<td>4 mm</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>Right</td>
<td>18.2</td>
<td>Normal</td>
<td>Normal</td>
<td>Abnormal</td>
<td>1 mm</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>Left</td>
<td>12.4</td>
<td>Normal</td>
<td>Normal</td>
<td>Yes (10)</td>
<td>1 mm</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>Left</td>
<td>12.5</td>
<td>Abnormal</td>
<td>Normal</td>
<td>Yes</td>
<td>2 mm</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>Right</td>
<td>25.3</td>
<td>Normal</td>
<td>Normal</td>
<td>Abnormal</td>
<td>9 mm</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>Left</td>
<td>15.5</td>
<td>Normal</td>
<td>Normal</td>
<td>Not done</td>
<td>1 mm</td>
<td>Yes‡</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>Left</td>
<td>14.0</td>
<td>Normal</td>
<td>Normal</td>
<td>No</td>
<td>3 mm</td>
<td>Yes§</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>Left</td>
<td>27.8</td>
<td>Abnormal</td>
<td>Abnormal</td>
<td>No</td>
<td>4 mm</td>
<td>Yes§</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>Left</td>
<td>15.5</td>
<td>Normal</td>
<td>Normal</td>
<td>No</td>
<td>9 mm</td>
<td>Yes§</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>Left</td>
<td>16.6</td>
<td>Normal</td>
<td>Normal</td>
<td>Abnormal</td>
<td>8 mm</td>
<td>Yes§</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>Left</td>
<td>25.9</td>
<td>Normal</td>
<td>Abnormal</td>
<td>No</td>
<td>10 mm</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>Right</td>
<td>12.4</td>
<td>Normal</td>
<td>Abnormal</td>
<td>Yes (CT 11)‡</td>
<td>8 mm</td>
<td>Yes§</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>Right</td>
<td>13</td>
<td>Normal</td>
<td>Abnormal</td>
<td>Yes</td>
<td>10 mm</td>
<td>Yes§</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>Right</td>
<td>12.1</td>
<td>Normal</td>
<td>Normal</td>
<td>Not done</td>
<td>12 mm</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

Patients 1 and 2, 3 and 4, 6 and 7, and 9 and 10 are sibs.

*ABR performed 6 years later. †ABR abnormal. §Missense mutation. ¶Large deletion. ‡Splice site mutation.

---

Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36

EDITOR—A report was recently published on the localisation of a chromosome segment at 1p36 which appeared to be linked (two point lod score=4.74) to a large number of families with multiple cases of early onset (mean age at diagnosis of <66 years) prostate cancer (PC) in which a brain tumour had been reported in a first or second degree relative of a PC case.1 This result is consistent with epidemiological evidence suggesting a familial relationship between brain cancer and PC as well as numerous studies of LOH at 1p36 in brain tumours.1 As part of the ACTANE (Anglo/Canadian/Texan/Australian/Norwegian/EU Biomed) familial PC Consortium, we have genotyped 207 multiple case PC families for five 1p36 tetranucleotide repeat polymorphisms, which were used by Gibbs et al.,1 and performed linkage analysis using GENEHUNTER2 with the following genetic map: D1S1160 - 3.835 cM - D1S1597 - 4.339 cM - D1S407 - 2.611 cM - GATA29A05 (=D1S3669) - 6.520 cM - D1S552. In addition to our interest in assessing our families for evidence of linkage of prostate and primary brain cancer to this region, we also wanted to determine if any other cancer site(s) might be associated with a susceptibility locus in this region. To this end, the family histories of all cancers were abstracted from the databases of several Consortium members and included in the analysis.

Table 1 presents the characteristics of the families; details on how they were ascertained are included in the footnotes. The criteria used for the prostate cancer familial clusters in this study are more relaxed than those suggested by the Hopkins group (referred to as the “Hopkins criteria” in the field).4 The linkage analysis results of nine prostate-brain cancer families were partitioned according to mean age at diagnosis of PC in the family; these results are shown in table 2. (Only two of these brain cancers have been confirmed by pathology reports; a glioma diagnosed at 67 years in a man who had three brothers with PC, mean age of diagnosis 66.7 years, and a glioblastoma diagnosed at 69 years in a family with five cases of PC, mean age of diagnosis 66.7 years, and a glioblastoma diagnosed at 69 years in a family with five cases of PC, mean age at diagnosis of 68.2 years). In the total set of nine families, all lod, NPL, and hlod scores maximised at D1S1160. Overall, we found no evidence of linkage of prostate-brain cancer to this region by either parametric (maximum lod score=−0.06) or non-parametric (NPL=0.25, p=0.39) analysis. The maximum lod was 0.07 at an alpha (proportion of families linked) of 48%. This latter estimate is consistent with the observation that four families had positive lod scores and four had negative scores (one family was uninformative, lod=0.0). Partitioning the families by mean age at diagnosis of PC resulted in suggestive, but not significant differential linkage with five early onset families (mean age at diagnosis <66 years) providing a maximum lod score of 0.48, whereas the remainder of the families appeared unlinked according to both lod score (−0.54) and NPL score (−0.20). These results are consistent with the lod scores of Gibbs et al. for families with a history of brain tumours when partitioned for average age at onset of prostate cancer, 3.65 (<66 years) and −1.84 (>66 years).

We then generated lod and NPL scores for all 207 families and sorted them according to these linkage results as well as by their mean age at PC diagnosis. In no case did a family history of any cancer at another site appear to cluster or be associated with linkage to 1p36 or with mean age at PC diagnosis. This analysis included examination by number and mean age at diagnosis of breast cancer in first degree relatives and all relatives, by number and mean age at diagnosis of ovarian cancers, number and mean age at diagnosis of colorectal cancer, stomach and pancreatic cancer, malignant melanoma, or uterine cancer. Although none of the family history groupings gave a positive lod score generally, they gave a positive score when the mean age at onset of PC was early. We therefore hypothesised that it might not be the family history of brain cancer that was responsible for positive linkage to 1p36 but, instead, the family history of early age at PC diagnosis per se.

Table 3 presents the linkage analysis results for the entire ACTANE pedigree set subdivided according to mean age at diagnosis of affected men in the family. The four age groups presented in table 3 were chosen to give approximately equal representation and are listed from the youngest (<50 years) to the oldest (>80 years). The large negative lod score for all the families, −9.66, rejects overall linkage to this region under the presumed genetic model of Carter et al.4 However, NPL score (1.02, p=0.15) and maximum lod (0.93, alpha=0.24) are consistent with the possibilities that either PC in a proportion of these families is the result of an autosomal dominant gene located at 1p36, or that alternative genetic models better explain the excess allele sharing among men with PC. Recessive and X linked models have not yet been tested in our family set.

Over the three subgroups of families with the earliest mean age at diagnosis, the sequential maximum lodcs (0.49, −2.89, −5.78), NPL scores (1.60, 1.02, 0.13), and heterogeneity lod scores (1.17, 0.59, 0.00) all indicate a
greater possibility of linkage the earlier the mean age at PC diagnosis. The NPL score in the group with the earliest mean age at diagnosis is close to being nominally significant (p=0.06), whereas for the other groups this score is not significant (p=0.15, 0.44, and 0.37, respectively). Also, as mean age of PC diagnosis increased, the estimated proportion of linked families decreased from 62% to 30% to 0%, also consistent with a general effect related to age at diagnosis. The group with the latest age at diagnosis does not appear to follow this pattern, but there are only 48 families in this class, and it might be expected that there would be a higher proportion of phenocopies in the upper liability class and this would decrease the power to detect linkage in this group. Although the reasons for this inconsistency are at present unclear, based on the results in the three youngest age groups, we feel that early age at diagnosis remains associated with an increased probability of linkage.

Our families provided no evidence that the putative familial prostate cancer locus, CAPB, at 1p36 is linked with primary brain tumours, or indeed cancer at any site other than the prostate. Although the five brain-prostate families with early mean age at diagnosis of PC did partition overall lod and NPL scores, we consider that because of the small number of families and the appearance of an age linkage score association when the families were subdivided by cancer at any site it remains unwarranted to postulate that susceptibility to brain tumours is increased by the inheritance of an altered gene in the 1p36 region. We found a possible overall association of linkage scores with mean age at diagnosis since families with earlier onset disease gave higher scores. Although not statistically significant, this result is similar to that found for HPC1 and PCAP as well as with other familial cancers such as breast and ovarian cancer.1 We note that table 6 of Gibbs et al suggested the possibility of linkage in 63 early onset PC families in that the lod scores were positive when the recombination fraction was 20% or more. However, linkage was tested only at D1S407 and Iod scores were not reported. Our maximum lod, NPL, and hlod scores generally occurred 5 to 9 cm centromeric to this position, so further analysis in this region in their PC family set would be of interest. There are several possibilities for the failure to detect linkage with the prostate cancer/primary brain phenotype in our families. The first is that the analysis by Gibbs et al may have led to a false finding arising from multiple subgroup analysis, which always has the risk of showing significant association by chance alone. The other, more interesting possibility, from the gene hunting perspective, is that it is not the primary brain phenotype per se that is linked to this region, but rather early onset PC, and it is this association with early onset disease which is important.

This study was supported by The Cancer Research Campaign, The EU BIOMED Programme Contract BMH4-CT96-1229, and The National Health and Medical Research Council of Australia. We would like to thank all the men and their families who took part in this study, Le Fond de la Recherche en Sant de Quebec (FRSQ), and Endorecherche. J Simard is a Senior Scientist from FRSQ. We would like to thank Martine Tranchant for her skilful technical assistance.

### Table 3. Linkage results from all 207 ACTANE families

<table>
<thead>
<tr>
<th>Mean age at onset</th>
<th>No of families</th>
<th>Max lod</th>
<th>Map*</th>
<th>NPL</th>
<th>p</th>
<th>Map</th>
<th>Het lod</th>
<th>a</th>
<th>Map</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>50–59</td>
<td>33</td>
<td>0.49</td>
<td>17.30</td>
<td>1.60</td>
<td>0.06</td>
<td>17.30</td>
<td>1.17</td>
<td>0.62</td>
<td>17.30</td>
<td>0.067</td>
</tr>
<tr>
<td>60–69</td>
<td>71</td>
<td>−2.89</td>
<td>14.69</td>
<td>1.02</td>
<td>0.15</td>
<td>10.78</td>
<td>0.59</td>
<td>0.30</td>
<td>10.78</td>
<td>0.260</td>
</tr>
<tr>
<td>70–79</td>
<td>55</td>
<td>−5.78</td>
<td>17.30</td>
<td>0.13</td>
<td>0.44</td>
<td>3.83</td>
<td>0.00</td>
<td>0.00</td>
<td>10.78</td>
<td>1.000</td>
</tr>
<tr>
<td>⩾80</td>
<td>48</td>
<td>0.95</td>
<td>10.78</td>
<td>0.31</td>
<td>0.37</td>
<td>10.78</td>
<td>0.95</td>
<td>0.88</td>
<td>10.78</td>
<td>0.110</td>
</tr>
<tr>
<td>Total</td>
<td>207</td>
<td>−9.66</td>
<td>15.99</td>
<td>1.02</td>
<td>0.12</td>
<td>3.83</td>
<td>1.93</td>
<td>0.24</td>
<td>12.08</td>
<td>0.011</td>
</tr>
</tbody>
</table>

*Map designates the genetic map distance (cM) from D1S1160 at which the maximum linkage score occurred.

---

**Comorbidity of 5,10-methylentetrahydrofolate reductase and methionine synthase gene polymorphisms and risk for neural tube defects**

**EDITOR—**Neural tube defects (NTDs) are among the most common and devastating birth defects. NTDs result from an incomplete closure of the neural tube, and include malformations of the skull, brain, meninges, spinal cord, and vertebral column. Recent evidence suggests that closure of the neural tube occurs in five separate sites which then fuse during the fourth week of gestation; NTDs occur when one site fails to close or two sites fail to fuse.1

During the last decade, periconceptional folic acid supplementation has been shown to reduce the risk of occurrence and recurrence of NTDs. Women with an NTD affected pregnancy do not usually have overt signs of folate deficiency, although decreased erythrocyte folate concentration, the index known to reflect whole body folate stores, has been reported. 2 In addition, it has been reported that women with NTD pregnancies have raised homocysteine concentrations in plasma and amniotic fluid, 3 suggesting that folate metabolism may be altered in these women.

5,10-methylentetrahydrofolate reductase (MTHFR) catalyses the reaction from 5,10-methylentetrahydrofolate to 5-methyltetrahydrofolate, which serves as methyl donor for the remethylation of homocysteine to methionine. A substitution (C to T) at the highly conserved nucleotide 677 of the MTHFR gene has been described, which results in the conversion of an alanine (Ala) to a valine (Val) residue and increased in vitro thermolability of the enzyme. 4 In vivo, the thermolabile MTHFR mutant is known to result in raised plasma homocysteine concentrations when folate nutrition is inadequate. 5 The frequency of homozygosity for this mutation is approximately 9% for various populations, but is higher in French Canadian, Italian, and Hispanic populations, and lower in African-American populations. 6,7,12

The C677T mutation has been reported to be a genetic risk factor for NTDs. 11,14,17 However, the significance of this mutation as an NTD risk factor in different populations has recently been questioned. Speer et al 8 found no evidence of MTHFR C677T polymorphism as a risk factor for lumbosacral spina bifida in American white patients. Weitkamp et al 9 also reported that the C677T polymorphism in MTHFR was not associated with NTD risk in a population of mixed ethnic origins. Papapetrou et al 10 found no evidence for an association between the 677T allele and the incidence of NTDs in a British population. Similarly, in French, German, and American populations, the distribution of the C677T mutation was the same in fetuses with NTDs and controls. 12,19,22 Ubbink et al 23 reported that homozygosity for the C677T mutation does not constitute a genetic risk factor for NTDs in rural South African blacks. The low frequency of MTHFR C677T polymorphism in African-Americans, 15 coupled with the lower incidence of NTDs in blacks, 16 suggests that analysis of the association between MTHFR polymorphisms and NTD risk in a large cohort of African-Americans would provide new information relative to the importance of this association in this population group. These investigations suggest that the frequency of this mutation and its associated risk for NTD may be population dependent or dependent on folate nutrition. It is possible that the MTHFR mutation predisposes the fetus to the development of NTDs, but they only occur if the maternal and/or fetal folate status are suboptimal; hence, periconceptional folic acid supplementation may overcome this genetic defect. Therefore, a careful evaluation of the effect of polymorphism in association with folate nutriture is warranted.

We recently reported that C677T MTHFR polymorphisms and raised homocysteine levels in amniotic fluid appeared to be disproportionately associated with NTDs spanning the cervical-lumbar spine, lumbosacral spine, and occipital encephalocoele. 24,25 These results suggest that periconceptional folic acid supplementation may prevent defects at these sites, but not at other sites of neural tube closure.

The gene for human methionine synthase (MS), which catalyses the reaction to form methionine from homocysteine, has recently been cloned, and a common polymorphism has also been identified. 17,26 The polymorphism is an A to G substitution at base pair (bp) 2756, converting an aspartic acid (Asp) residue into a glycine (Gly). Although MS plays an important role in homocysteine metabolism, this polymorphism has not been reported to be a risk factor for NTD formation 30,35 and, to our knowledge, comorbidity of MTHFR and MS polymorphisms for NTDs has never been evaluated. Potential comorbidity of these enzymes may be of significance because MS and MTHFR are both key enzymes in homocysteine metabolism, and altered homocysteine metabolism has been implicated in the development of NTDs. 4,7

We determined MTHFR and MS genotypes using DNA isolated from amniotic fluid cells of fetuses with NTDs and of those without any apparent malformations, and evaluated potential associations between polymorphisms in these two genes as a risk factor for the development of NTDs. The study was approved by the Institutional Review Board of the University of Alabama at Birmingham. The computerised genetics database at the University of Alabama Prenatal Genetics Clinic was used to identify cases in which NTDs were diagnosed by ultrasound and amniocentesis, and confirmed by neonatal examination or necropsy, between 1988 and 1997. Excess stored second trimester amniotic fluid samples from 82 women with fetuses with confirmed NTDs (cases) and from 84 women with normal pregnancies (controls) were analysed. For each case selected, we identified control samples obtained from women who had undergone amniocentesis at the same clinic but had a fetus confirmed to be normal by ultrasound, karyotype, and newborn examination. Each acceptable control was randomly assigned a computer generated priority number (SASS RANUI function) and sorted accordingly. Samples were then retrieved from storage according to their priority number; the first adequate sample located was selected as a control. Cases and controls were matched for race, maternal age, and month and year of amniocentesis. The case and control groups each had a composition of 83% white, 16% African-American, and 1% other. The mean (SD) maternal ages of cases and controls were not significantly different (26.3 (SD 5.3) and 28.1 (SD 4.9) years, respectively).

The amniotic fluid samples were collected aseptically under ultrasound guidance by an experienced operator, and were stored at −70°C until analysis. A 200 µl aliquot of amniotic fluid was centrifuged for five minutes at 13 000 g. After removing 150 µl of supernatant, the remaining pellet (50 µl) was suspended in 300 µl Cell Lysis Solution and DNA was isolated (Puregene DNA Isolation Kit, Gentra Systems, Minneapolis, MN). Isolated DNA was resus-
Our findings using amniotic fluid cells indicate that fetuses homozygous or heterozygous for the C to T substitution in the MTHFR gene are at increased risk for NTDs. In order to compare our results to those of others, we summarised the MTHFR genotype frequencies in previously reported NTD cases from all studies with ≥50 subjects (table 3). We selected studies with NTD cases exceeding 50 subjects. Our study, reporting the MTHFR genotype of 82 NTD cases and 76 controls, is the fourth largest study in terms of the number of NTD cases. Our results are similar to those of previous studies which suggested that either homozgyosity or heterozygosity for the C677T mutation in the fetal MTHFR gene is a risk factor for NTDs. A meta-analysis of the available data indicated that homozgyosity for the C677T mutation resulted in an approximately two-fold increase of risk for NTDs.11 In the study reported here, we found that NTD risk was increased in fetuses having the Val/Val and Ala/Val genotypes. When compared to previous studies, our odds ratios for both heterozygous and homozygous MTHFR C677T genotype frequencies in NTD cases are higher than those previously reported. The mechanism accounting for the higher ratios is unknown, but may relate to the ethnic or geographical composition or the folate nutriture of our study population. Folate nutriture is mentioned here because previous studies have shown that folic acid supplementation decreases the incidence of NTDs.25

Our finding of no association between the A2756G (Gly/Gly) polymorphism in the MTHFR gene and the occurrence of the NTD phenotype is similar to that of van der Put et al,26 who reported that there is no increased prevalence of the Asp/Gly or Gly/Gly genotypes in fetuses with NTDs or their mothers. They found that the prevalence in controls of the Asp/Asp, Asp/Gly, and Gly/Gly genotypes was 71%, 26%, and 3%, respectively, which is similar to our values of 84%, 14%, and 3% in controls presented here. Shaw et al27 and Morrison et al28 also reported that overall percentages of Asp/Gly and Gly/Gly were not increased in infants with NTDs. Christensen et al29 presented data suggesting that the homozygous mutant genotype for the A2756G polymorphism in methionine synthase was associated with a reduced risk for NTD in children. Given the importance of MS in homocysteine metabolism, it is tempting to speculate that during the course of evolution, some mutations of MS were so deleterious that they were lethal to the fetus and were thus not propagated.

To our knowledge, this is the first reported study of interactions between frequently occurring polymorphisms of two genes involved in folate metabolism. We did not find strong associations between MTHFR and MS polymorphisms and the risk of NTDs. van der Put et al26 recently hypothesised that combined heterozygosity for two common MTHFR mutations may be an additional risk factor for NTDs. The significance, if any, of the weak MS/MTHFR associations that were observed in this study requires further evaluation, and possible confounding factors resulting from genetic associations involved in folate metabolism as well as folate nutriture may warrant further investigation.

**Table 1** Odds ratios and 95% confidence intervals of 5,10-methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) genotypes in fetuses with NTDs (cases) and controls

<table>
<thead>
<tr>
<th>Genotype</th>
<th>NTDs (cases)</th>
<th>Controls</th>
<th>Odds ratio</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTHFR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ala/Ala</td>
<td>43/82 (52%)</td>
<td>63/76 (83%)</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Ala/Val</td>
<td>30/82 (37%)</td>
<td>11/76 (14%)</td>
<td>4.0</td>
<td>1.8–8.8</td>
</tr>
<tr>
<td>Val/Val</td>
<td>9/82 (11%)</td>
<td>2/76 (3%)</td>
<td>6.6</td>
<td>1.3–24.9</td>
</tr>
<tr>
<td>MS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asp/Asp</td>
<td>59/77 (77%)</td>
<td>70/84 (83%)</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Asp/Gly</td>
<td>18/77 (23%)</td>
<td>13/84 (14%)</td>
<td>1.6</td>
<td>0.7–3.6</td>
</tr>
<tr>
<td>Gly/Gly</td>
<td>0/77 (0%)</td>
<td>1/84 (1%)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

pended in 25 µl Tris-EDTA buffer and stored at −20°C until analysis. The C677T mutation in the MTHFR gene was determined by polymerase chain reaction (PCR) amplification of DNA using an exonic and intronic primer pair that generates a 189 bp fragment.28 Thirty eight cycles of PCR were performed for one minute at 94°C, one minute at 60°C, and two minutes at 72°C, followed by a 10 minute elongation at 72°C at the end of the cycles. The A2756G polymorphism in the MS gene was determined by PCR amplification using a primer pair that generates a 198 bp fragment.29 Thirty eight cycles of PCR were performed for 45 seconds at 95°C, 35 seconds at 55°C, and 75 seconds at 72°C. An aliquot of the PCR product was digested overnight with Hinfl restriction endonuclease (for detecting MTHFR) or with HaeIII (for detecting MS).29 The reaction products were subjected to electrophoresis using a 1.8% agarose gel. The homozygous normal MTHFR and MS alleles are not digested by their respective restriction endonucleases, whereas the polymorphisms create recognition sequences which are digested. The non-mutated (Ala/Ala) MTHFR PCR product is 198 bp long. The homozygous mutant (Val/Val) allele is thus digested completely by the enzyme and gives a 175 bp fragment and a 23 bp fragment. The latter runs off the gel and is not visible after electrophoresis. The heterozygous genotype (Ala/Val) yields both the 198 and 175 bp fragments upon Hinfl digestion. Similarly, the non-mutated (Asp/Asp), homozygous mutant (Gly/Gly), and heterozygous (Asp/Gly) genotypes of MS yield 189, 159, and 189 plus 159 bp bands, respectively.

As shown in table 1, we found that the C677T Ala/Val or Val/Val MTHFR genotype was more prevalent in NTD cases than in controls. When Ala/Val and Val/Val genotypes were combined, 48% of NTD cases had both alleles, compared with 17% of controls. There was a 4.0-fold increased risk for NTDs in fetuses having the Ala/Val genotype (95% confidence interval 1.8–8.8), and the risk increased to 6.6-fold in fetuses with the Val/Val genotype (95% confidence interval 1.3–24.9). The fetal MS A2756G Gly/Gly and Asp/Gly genotypes were not associated with risk of NTD (table 1). Furthermore, we also found no association between combined MTHFR and MS polymorphisms and risk of NTDs (table 2).

**Table 2** Odds ratios and 95% confidence intervals of 5,10-methylenetetrahydrofolate reductase (MTHFR) and methionine synthase (MS) genotypes in fetuses with NTDs (cases) and controls

<table>
<thead>
<tr>
<th>MTHFR genotype</th>
<th>MS genotype</th>
<th>NTDs (cases)</th>
<th>Odds ratio</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ala/Ala</td>
<td>Asp/Asp</td>
<td>32</td>
<td>53</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td>Asp/Gly</td>
<td>8</td>
<td>9</td>
<td>1.5</td>
</tr>
<tr>
<td></td>
<td>Gly/Gly</td>
<td>0</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td>Ala/Val</td>
<td>Asp/Asp</td>
<td>22</td>
<td>10</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td>Asp/Gly</td>
<td>7</td>
<td>3</td>
<td>3.2</td>
</tr>
<tr>
<td></td>
<td>Gly/Gly</td>
<td>0</td>
<td>0</td>
<td>—</td>
</tr>
<tr>
<td>Val/Val</td>
<td>Asp/Asp</td>
<td>5</td>
<td>1</td>
<td>1.0</td>
</tr>
<tr>
<td></td>
<td>Asp/Gly</td>
<td>3</td>
<td>1</td>
<td>—</td>
</tr>
<tr>
<td></td>
<td>Gly/Gly</td>
<td>0</td>
<td>0</td>
<td>—</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No of NTD cases</th>
<th>No. heterozygous (%)</th>
<th>No. homozygous (%)</th>
<th>Homozygous odds ratio</th>
<th>95% confidence interval</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>214</td>
<td>100 (47)</td>
<td>41 (19)</td>
<td>—</td>
<td>—</td>
<td>12</td>
</tr>
<tr>
<td>153</td>
<td>Not reported</td>
<td>29 (19)</td>
<td>—</td>
<td>—</td>
<td>16</td>
</tr>
<tr>
<td>137</td>
<td>60 (44)</td>
<td>19 (14)</td>
<td>—</td>
<td>—</td>
<td>19</td>
</tr>
<tr>
<td>82</td>
<td>32 (39)</td>
<td>15 (18)</td>
<td>—</td>
<td>—</td>
<td>14</td>
</tr>
<tr>
<td>56</td>
<td>26 (46)</td>
<td>11 (20)</td>
<td>2.2</td>
<td>0.8–6.0</td>
<td>26</td>
</tr>
<tr>
<td>55</td>
<td>26 (47)</td>
<td>7 (13)</td>
<td>2.9</td>
<td>1.0–7.9</td>
<td>15</td>
</tr>
<tr>
<td>82</td>
<td>30 (37)</td>
<td>9 (11)</td>
<td>6.6</td>
<td>1.3–24.9</td>
<td>Our study</td>
</tr>
</tbody>
</table>

www.jmedgenet.com
Expression of HCM causing mutations: lessons learnt from genotype-phenotype studies of the South African founder MYH7 A797T mutation

EDITOR—Genotype-phenotype correlations provide another perspective in studies seeking to identify the factors that underlie the clinical variability that is a feature of several inherited diseases. This approach has been particularly revealing in investigations into the molecular causes and phenotypic heterogeneity associated with hypertrophic cardiomyopathy (HCM), a common inherited primary cardiac disorder. Although, as its name suggests, hypertrophy may be a noticeable feature of the disease, it is not invariant, nor does the degree of hypertrophy necessarily correlate with the risk of sudden cardiac death (SCD), which is the most feared consequence of HCM.1

1 Molecular genetic investigations have shown that HCM is caused by more than 100 distinct mutations in at least seven different sarcomeric protein encoding genes.2 When the clinical features of HCM are correlated in a family context with the specific disease causing gene and its associated mutation, a recognisable pattern emerges. Essen-
tially, mutations in the cardiac β myosin heavy chain gene (MYH7) are more often associated with echocardiographically detectable to marked hypertrophy and a variable risk of SCD, usually before the age of 35 years, which generally relates to the specific causative mutation.9 In striking contrast, mutations in the cardiac troponin T gene (TNNT2) are most frequently accompanied by subtle, or even undetectable, hypertrophy, yet confer a high risk of SCD in adolescence or young adulthood.1,4 Between these extremes lie the myosin binding protein C gene mutations, which are responsible for a considerably later age of onset of a steadily progressive form of hypertrophy, which may result in death from congestive heart failure later in life, more often than SCD.1,4 Further studies are needed before conclusive genotype-phenotype profiles can be defined for mutations in other HCM causing genes.9–11

This stratification of HCM into distinguishable subclasses of disease has been used in prognostication and management and counselling of patients with this treatable, but currently incurable, disease. However, it is generally advised that this approach be undertaken with caution, as some phenotypic associations are based on limited patient numbers.1,4 Furthermore, there is concern that data generated for one ethnic group cannot necessarily be extrapolated to others.1,4 As a corollary, evidence suggests that diverse genetic and environmental susceptibility factors may modulate the expression of identified disease causing mutations in the sarcomeric protein encoding genes.4,15

We previously described a novel MYH7 mutation, resulting in the substitution of a threonine (T) residue for an alanine (A) residue at codon 797 (A797T), in two South African HCM patients. Initial impressions, based on the immediate family history of one of these unrelated subjects, were that this mutation was associated with a poor prognosis and frequent SCD, thus prompting further investigation.16 It was then found that both parents of the proband carried the MYH7 A797T mutation. Concomitantly, this mutation was identified in another seven apparently unrelated members of a panel of South African HCM patients. Subsequent haplotyping studies showed that the MYH7 A797T mutation was a founder mutation extant in South African subpopulation groups, where it accounted for 25% of disease causes in a panel of HCM affected probands,17 making it even more important to investigate its associated phenotype. These studies were further warranted because the mutation carriers in the extended families traced from these probands shared a common ancestor and provided a large patient base in which to establish genotype-phenotype correlations.

We show that the MYH7 A797T mutation is generally associated with a favourable prognosis, but that it is important to consider the influence of both genetic and environmental modifiers on the disease profile, when using genotype-phenotype correlations in patient management and counselling.

The study subjects were probands belonging to a panel of South African HCM affected subjects and their relatives who could be traced. After obtaining informed consent from subjects or legal guardians, DNA was extracted from peripheral blood samples.9 The MYH7 A797T mutation was detected by PCR based allele specific restriction enzyme analysis.18 Mutation positive subjects were clinically evaluated as described previously.19 Briefly, echocardiographically determined end diastolic maximum left ventricular wall thickness (LVWT) measurements were obtained at the anterior interventricular septum (IVS) and posterior wall (PW). Echocardiographic diagnosis of HCM was made in the presence of an IVS >13 mm, in the absence of confounding factors. Electrocardiographic diagnosis of HCM was based on the presence of left ventricular hypertrophy (LVH) according to the point system of Romhilt and Estes19 or a significant Q wave abnormality. A family history and clinical records were obtained to identify the range of the symptoms noted in affected subjects and the number of disease related and sudden cardiac deaths (SCDs) reported among the families studied. The latter data were used to construct Kaplan-Meier survival curves.20 Based on the similarity of phenotype and survival, the survival data from affected subjects in all the families, except those belonging to pedigree 101, were pooled. Pedigree 101 was evaluated separately because both parents in kindred 101a (fig 1) carried the MYH7 A797T mutation and previous haplotype studies had shown them to be related.21 Members of the pedigrees are identified by a pedigree number prefix, followed by the subject’s identification numbers. The prefix SB identifies probands from whom relatives could not be traced. Pedigrees 101, 124, 131, and 138 were of white descent, while pedigrees 104 and 110 and subjects SB902, SB983, and SB995 were of ethnic admixture.17 In order to ascertain that two brothers carrying the MYH7 A797T mutation were monozygotic (MZ) twins, their HindIII digested DNA samples were analysed by Southern blot hybridisation11 at hypervariable G TG genetic loci using the (G TG), fingerprinting probe.22

A total of 66 family members of six pedigrees (pedigrees 101, 104, 110, 124, 131, and 138, fig 1) and three probands (SB902, SB983, and SB995) were genotyped for the MYH7 A797T mutation. Of these, 39 were mutation carriers (table 1), including both parents (1.II.2 and 1.II.3) of the proband (1.III.6) of kindred 101a, within pedigree 101 (fig 1). Additionally, three dead sibs of 1.II.6, namely 1.III.1, 1.III.3, and 1.III.5, were diagnosed with HCM at necropsy, implying that they were likely to have inherited at least one copy of the mutant allele from one of their carrier parents. Of these subjects, 1.III.1 was definitely a heterozygous mutation carrier, as one of her fraternal twin siblings 1.IV.2 had inherited the mutation, while the other (1.IV.1) had not. Similarly, dead subject 1.III.3 could not have been a homozygous mutation carrier, as he also had one non-carrier child (1.IV.3). No further assumptions could be made about the carrier status of dead subject 1.III.5, who died childless. No living homozygous mutation carriers were detected in this branch of pedigree 101.

Thirty five of the 39 living mutation carriers were clinically examined, while 1.III.10, 4.II.3, 4.III.1, and 38.III.1 declined clinical investigation. Subjects 38.II.1, 38.II.6, and 38.III.3 were assessed only by ECG and 4.II.1, 4.III.1, and 10.II.1 only by echocardiography.

The mutation was associated with echocardiographically detectable hypertrophy of the IVS (LVWT >13 mm) in 17 subjects (table 1), and although not to the same extent, the left PW and/or apex were also abnormal, with measurements of greater than 11 mm, in 11 of these subjects (table 1). Additionally, there were three mutation carriers whose LVWT measurements were ≥11 but <13 mm. Moreover, SB902 and SB983 had undergone myectomy to reduce outflow tract obstruction, as well as mitral valve replacement. The mean LVWT, calculated for all mutation carriers ≥16 years, was 17.1 mm (SD 8.6), while the median LVWT was 13 mm.

Blood pressure measurements were below 160/95 mm Hg in 27 of the 29 mutation carriers for whom records were available (table 1), with the exceptions being two brothers, 31.III.6 and 31.III.8 (160/110 and 150/100 mm Hg, respectively). Only three of these 29 mutation carriers were receiving blood pressure lowering medication at the
time of the initial examination, namely, 31.III.6, who suffered kidney disease, and 31.III.8 and 31.III.1.

Only four subjects had electrocardiographically detectable LVH, evaluated by the point system of Romhilt and Estes\(^1\); these subjects had also shown an LVWT of \(>13\) mm (table 1). Additionally, 1.III.6 had had a pacemaker inserted. A further 12 subjects had other ECG abnormalities often noted in HCM, while their LVWT values varied between 10 and 40 mm. Of the remaining 15 subjects who did not display any ECG abnormalities, nine also did not meet the echocardiographic diagnostic criterion, while two had not been investigated by echocardiography and three were less than 16 years old (table 1).

Disease penetrance among all mutation carriers was 61\% (19/35 subjects), based on subjects older than 16 years for whom an LVWT of \(>13\) mm was measured (32 subjects, table 1) or who were diagnosed with HCM at necropsy (three subjects).

The symptomatic presentation of mutation carriers varied. Six of the 35 subjects for whom data were available complained of syncope or presyncope (1.II.2, 1.II.8, 1.III.6, 1.III.8, 31.III.4, SB902), three experienced dyspnoea (1.II.3, 1.III.8, 4.II.1), four suffered palpitations (1.II.8, 4.II.1, 31.III.1, 38.II.4), while six experienced both dyspnoea and palpitations (1.III.6, 1.IV.2, 10.II.1, SB902, SB983, SB995). Five subjects experienced angina (1.II.8,
1.III.6, 38.II.4, SB902, SB995), two suffered cardiac failure (1.II.2, 4.I.1), while three subjects developed both angina and cardiac failure (1.II.3, 4.II.1, SB983). However, further investigation of possible underlying ischaemic heart disease was not undertaken. Of the 35 clinically assessed mutation carriers, 19 subjects, of whom four were under 16 years of age, had no reported symptoms.

Proband 38.II.4 (fig 1) presented with chest pain and palpitations at the age of 38 years. He showed an LVWT of 12.7 mm at both the IVS and the left PW, and while his ECG tracings showed abnormal repolarisation and increased voltages (table 1), they did not meet the diagnostic criterion of LVH. However, taken together, the mild LVH, non-specific ECG changes, and symptoms, were likely to be HCM related. In contrast, his twin brother, 38.II.5, who was identified by band sharing on GTG fingerprinting, was symptom free, and exhibited an LVWT of 10 mm at the PW and 9 mm at the IVS. Although on ECG, 38.II.3 exhibited the same repolarisation abnormality and increased voltages as his twin, all other parameters, including similar blood pressure values, were normal. It was established from the proband’s history that, while he had always been physically active, playing rugby football in high school and continuing to participate in competitive recreational cycling at the age of 38 years, his twin brother had generally avoided sport and exercise.

In kindred 101a, three of the four offspring of parents 1.II.2 and 1.II.3 had suffered SCD (fig 1). These events occurred in 1.III.1, 1.III.3, and 1.III.5 at 26 weeks to 29 years, and 17 years of age, while they were walking, playing tennis, and during a period of heightened emotion, respectively. Three of their mother’s pregnancies had terminated in spontaneous abortions and she suffered SCD while sedentary at the age of 58 years. In contrast, no sudden, or disease related, deaths were known to have occurred in the recent generations of any of the other pedigrees, including the remainder of pedigree 101. In pedigree 131, one pregnancy in 31.II.3 had miscarried. The hypertensive father of the proband in pedigree 138 had died at 58 years of myocardial infarction, probably resulting from ischaemic heart disease. The Kaplan-Meier product limit curves for survival of the subjects with the MYH7 A797T mutation belonging to pedigree 101 and that of the rest of the families with this mutation, as well as that of South African families carrying the R92W mutation in TNNT2, are shown in fig 2. While survival in the other pedigrees was unaltered, survival in pedigree 101 was comparable to that of subjects bearing the TNNT2 R92W mutation with its previously described poor prognosis.

In this study, we have investigated the clinical phenotype associated with the HCM causative MYH7 A797T mutation in 35 mutation carriers, of whom 32 were members of six different apparently unrelated pedigrees, and three were from families who could not be traced. The present study shows that, although the initial impressions were to the contrary, the MYH7 A797T mutation was generally associated with a good prognosis and normal life span, except in kindred 101a (figs 1 and 2).

However, despite the usually favourable prognosis, the mutation was generally associated with echocardiographically detectable to overt hypertrophy, which was often marked (table 1). Two mutation carriers, SB902 and

Table 1  Echocardiographic and electrocardiographic features present in subjects carrying the A797T MYH7 mutation

<table>
<thead>
<tr>
<th>Echocardiographic</th>
<th>Electrocardiographic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subject No</strong></td>
<td><strong>Sex/age (y)</strong></td>
</tr>
<tr>
<td>1.II.2</td>
<td>M/58</td>
</tr>
<tr>
<td>1.II.3</td>
<td>F/55</td>
</tr>
<tr>
<td>1.II.6</td>
<td>F/93</td>
</tr>
<tr>
<td>1.II.8</td>
<td>F/47</td>
</tr>
<tr>
<td>1.III.3</td>
<td>M/34</td>
</tr>
<tr>
<td>1.III.8</td>
<td>M/29</td>
</tr>
<tr>
<td>1.III.10</td>
<td>M/10</td>
</tr>
<tr>
<td>1.III.11</td>
<td>F/27</td>
</tr>
<tr>
<td>1.IV.2</td>
<td>F/14</td>
</tr>
<tr>
<td>1.IV.8</td>
<td>F/8</td>
</tr>
<tr>
<td>1.IV.10</td>
<td>F/70</td>
</tr>
<tr>
<td>1.IV.27</td>
<td>M/48</td>
</tr>
<tr>
<td>1.IV.3</td>
<td>M/34</td>
</tr>
<tr>
<td>1.IV.31</td>
<td>F/33</td>
</tr>
<tr>
<td>1.IV.33</td>
<td>F/10</td>
</tr>
<tr>
<td>1.IV.34</td>
<td>F/10</td>
</tr>
<tr>
<td>1.IV.35</td>
<td>F/10</td>
</tr>
<tr>
<td>1.IV.36</td>
<td>M/10</td>
</tr>
<tr>
<td>1.IV.37</td>
<td>M/9</td>
</tr>
<tr>
<td>1.IV.38</td>
<td>M/7</td>
</tr>
<tr>
<td>1.IV.39</td>
<td>M/26</td>
</tr>
<tr>
<td>1.IV.40</td>
<td>M/22</td>
</tr>
<tr>
<td>1.IV.41</td>
<td>M/19</td>
</tr>
<tr>
<td>1.IV.42</td>
<td>M/10</td>
</tr>
<tr>
<td>1.IV.43</td>
<td>M/10</td>
</tr>
<tr>
<td>1.IV.44</td>
<td>M/9</td>
</tr>
<tr>
<td>1.IV.45</td>
<td>M/9</td>
</tr>
<tr>
<td>1.IV.46</td>
<td>M/3</td>
</tr>
<tr>
<td>1.IV.47</td>
<td>M/35</td>
</tr>
<tr>
<td>1.IV.48</td>
<td>F/11</td>
</tr>
<tr>
<td>1.IV.49</td>
<td>F/13</td>
</tr>
<tr>
<td>1.IV.50</td>
<td>F/32</td>
</tr>
<tr>
<td>1.IV.51</td>
<td>M/49</td>
</tr>
</tbody>
</table>

Abnormal Q waves = abnormal Q waves, Abn rep = abnormal repolarisation, Age = age at diagnosis, ASH = asymmetrical septal hypertrophy, ↑Atria = enlarged atria, BP = blood pressure (mm Hg), Inc volts = increased voltages, IVS (mm) = maximum end diastolic interventricular septal thickness in mm, Ivs = interventricular septum, LVH = left ventricular hypertrophy by Romhilt and Estes’s criteria, PW (mm) = maximum end diastolic posterior wall thickness in mm, PW = posterior left ventricular free wall, SAM = systolic anterior motion of the mitral valve, y = feature present, n = feature absent, NA = not applicable, na = records not available, NI = not investigated clinically, * = post myocardial values. Subjects under 16 years old are underlined.
SB983, had undergone septal myectomy, to reduce outflow tract obstruction resulting from their cardiac hypertrophy, as well as mitral valve replacement. The mean (SD) LVWT in all the pedigrees, excluding pedigree 101, was 17.8 (SD 8.7 mm), with a range of 8-40 mm for subjects over 16 years old (table 1). In pedigree 101, the mean (SD) LVWT was similar to these values, namely 16.6 (SD 9.6 mm), with a range of 9-36 mm, which was shown by ANOVA to have no statistically significant difference from the rest of the families with this mutation.

When considering survival, the only exception to the good prognosis associated with the MYH7 A797T mutation was in pedigree 101. Here, the high frequency of SCD was restricted to kindred 101a (figs 1 and 2), in which haplotyping studies had previously indicated that the parents of the proband, both of whom carried the MYH7 A797T mutation, shared a common ancestor.17 Three of the four offspring of the related mutation carrier parents in kindred 101a had died suddenly, before the age of 27 years. It is unlikely that these deaths resulted from a dosage effect of the mutant myosin protein, as at least two of them (1.III.1 and 1.III.3) could not have been homozygous mutation carriers by virtue of their non-carrier offspring (fig 1). In contrast to the poor prognosis observed in kindred 101a, the mutation was not associated with any disease related deaths in the rest of pedigree 101, nor in the other families carrying the MYH7 A797T mutation (figs 1 and 2).

The data generated from genotype-phenotype assessments has led to speculation that HCM is not a simple monogenic disorder, as frequently the clinical manifestations and course of the disease differ even between subjects in the same family.14 15 For example, in the present study, there was marked variation in the degree of LVWT associated with the MYH7 A797T mutation within members of the same pedigree (table 1), indicating that the phenotypic expression of HCM causing mutations is modulated by additional factors. Whether these factors are genetic or environmental, and what the nature of the interplay between these factors and the major HCM causing mutations are, has been a topic of discussion in recent papers.15 25

It can be speculated that the distinctive survival curve seen in pedigree 101 may result from the influence of genetic factors. In view of the shared ancestry of the parents in the nuclear family, it is possible that their offspring, who were deduced not to be MYH7 A797T homozygotes, may have been homozygous for susceptibility alleles at other loci that play a role in modulating expression of the main disease causative gene. Further support for the influence of deleterious homozygosity is that while the proband, 1.III.6, the remaining living child of parents sharing a common ancestor, showed overt septal hypertrophy (36 mm), and had undergone pacemaker implantation, his half brother, 1.III.8, showed moderate hypertrophy (13 mm). However, as the degree of relatedness of the parents in kindred 101a could not be established, this proposal remains speculative. It is unlikely that environmental factors alone could account for the malignant phenotype seen only in kindred 101a, as the clinical course associated with the founder mutation was benign in all other affected families, whose individual members were exposed to varied environments and lifestyle.

Evidence that environmental factors may also play a role in modulating the expression of main locus HCM causing mutations is provided by the divergent clinical presentation associated with the MYH7 A797T mutation in the identical twin brothers in pedigree 138. Whereas, the physically active twin, 38.II.4, was symptomatic and showed an LVWT of 12.7 mm, with the hypertrophy appearing concentric and concentrated around the apex, the LVWT in his asymptomatic brother, 38.II.3, measured only 10 mm. Earlier studies have also documented heterogeneity in the clinical expression of HCM in MZ twins,24 25 but this is the first report of MZ twins genotyped for a specific HCM causing mutation, in which clinical differences may directly relate to exercise. The influence of physical activity on the expression of the hypertrophic phenotype in HCM has been a cause of speculation, as exercise is known to produce the hypertrophy seen in “athletes’ heart”.26 However, although these twins were considered genetically identical, it cannot be excluded that epigenetic factors, or indeed environmental influences other than exercise, could also have played a role in the dissimilar development of hypertrophy.

Currently, genotype-phenotype correlation studies provide the best available route to informed and accurate prognosis for improved patient management and risk stratification, with the caveat that these correlations should be based on substantial numbers of subjects drawn from the relevant ethnic group. In addition, it may also be prudent to consider

---

**Figure 2** A comparison of Kaplan-Meier product limit curves for survival in subjects carrying the MYH7 A797T mutation and those carrying the previously reported TNNT2 R92W mutation.17 Survival data were combined and plotted for all MYH7 A797T families except for pedigree 101. Survival in pedigree 101 was similar to that of subjects with the TNNT2 R92W mutation (p=0.9), but was significantly worse than in the other families with the MYH7 A797T mutation (p=0.024).
Germline and somatic mosaicism in achondroplasia

EDITOR—We describe a sib recurrence in achondroplasia with parents of normal stature. Both affected offspring carried the same (gain-of-function) mutation (G1138C) in the fibroblast growth factor receptor 3 (FGFR3) gene. Despite having no clinical features of achondroplasia, a proportion of the mother’s peripheral blood leucocytes also contained the mutant FGFR3 allele. We conclude she is a germline and somatic mosaic for achondroplasia and that both children have inherited the condition from her. To our knowledge, this is the first confirmed case of germline mosaicism in achondroplasia.

Achondroplasia is the commonest form of short limbed dwarfism (birth incidence estimated at between 1:10 000 and 1:70 000) and is transmitted as an autosomal dominant trait. As is often the case among dominant traits, a high proportion of cases are new mutations but a proportion are caused by one of two mutations at the same nucleotide in FGFR3 (G1138A transition and G1138C transversion).1 In common with other FGFR3 mutations which cause skeletal dysplasia, the pathogenic effect of the achondroplasia mutation is thought to be altered mitogenesis and/or differentiation owing to constitutive activation of the receptor.2 There is a marked paternal age effect in achondroplasia and it has recently been shown that new mutations in achondroplasia are almost exclusively of paternal origin.3 We received

blood leucocytes was determined using primer extension to

the relative proportion of the G1138C allele in the mother’s

expected for a straightforward heterozygote (fig 1). The

wild type allele was less than the 1:1, which would be

However, the ratio of the G1138C allele compared to the

mutation in his blood but, surprisingly, the mother did.

Analysis showed that both children were heterozygous for

the rare G1138C transversion. The father did not have the

mutation in his blood but, surprisingly, the mother did.

However, the ratio of the G1138C allele compared to the

wild type allele was less than the 1:1, which would be

expected for a straightforward heterozygote (fig 1). The

relative proportion of the G1138C allele in the mother’s

blood leucocytes was determined using primer extension

(1) followed by densitometry. The proportion of the

mutant allele in the mother was found to be 28%. She has a

height of 169 cm, span of 171 cm, upper segment/lower

segment 0.09, left hand 17.6 cm, and head circumference

of 58 cm. Apart from her slightly larger head size and mild

obesity her appearance is normal.

We conclude that, despite her normal appearance, the

mother is a germline and somatic mosaic for the G1138C

mutation and both her affected children have inherited the

mutant allele from her. Given the mother’s relatively high

proportion of mutant alleles, her lack of phenotypic

expression is surprising; a hypochondroplasia-like pheno-
type, which is less severe than achondroplasia, might have

been expected. The most likely explanation for this is the

tissue specific distribution of the mosaicism, although the

mutant allele is present in 28% of her peripheral blood

leucocytes it may be at lower levels in her chondrocytes.

Germline and somatic mosaicism are both reasonably

common features of genetic disorders. For example, in

Duchenne muscular dystrophy and osteogenesis imperfecta, 15% and 6% of cases, respectively, inherit the con-
dition from a detectably mosaic parent.1 Germline mosaici-

The primer

The products were then separated by electrophoresis through a 15%
denaturing polyacrylamide gel. The relative intensity of the 24mer

and 25mer products was used to calculate the proportion of achondroplastic to

wild type allele. Lane order and PCR primers as above.

findings that somatic activating mutations of FGFR3 are

relatively common in multiple myeloma3 and carcinomas.5

However, all the FGFR3 mutations so far identified in

these malignant neoplasms are identical to activating

mutations that cause thanatophoric dysplasia. The greater

severity of this phenotype in comparison to achondro-

plasia is thought to be a reflection of the more strongly

activating nature of the thanatophoric dysplasia muta-
tions.10 That only these highly activating FGFR3 muta-
tions so far have been found in neoplasms may suggest

that the achondroplasia mutations, when they occur in

somatic cells, do not activate the receptor to a level that it

becomes oncogenic.

This is the first confirmed report of germline and

somatic mosaicism for an achondroplasia mutation. The

FGFR3 nucleotide 1138 appears to be highly mutable in

the male germline, but somatic mutations resulting in

mosaicism are rare. The reasons for this discrepancy are

unknown but are clearly of importance to the under-

standing of mutagenesis. The observation that the mother has a

normal appearance, despite a high proportion of the

achondroplastic allele in her somatic tissues, exemplifies

the fine balance that the fibroblast growth factors play in

morphological determination.

SHIRLEY HENDERSON†

DAVID SILENCE†

JOHN LOUGHLIN*
Achondroplasia with the $FGFR3$ $1138g\rightarrow a$ (G380R) mutation in two sibs sharing a 4p haplotype derived from their unaffected father

Editor—The study of achondroplasia, the most frequent skeletal dysplasia in man, has contributed several important insights into both developmental biology and human genetics, such as the recognition of the paternal age effect for dominant mutations, the first indication of the importance of FGFR molecules in growth and development, and the identification of the nucleotide with the highest mutation rate known so far in man, nucleotide 1138 of the $FGFR3$ gene. Most cases of achondroplasia are associated with the $g\rightarrow a$ transition at nucleotide 1138 of $FGFR3$.

In spite of the frequency of achondroplasia, the birth of two or more children with achondroplasia to unaffected parents is surprisingly rare, with only a few examples published. One instance of half sibs with achondroplasia born to the same father has been reported. In contrast, somatic mosaicism unlikely.


8 Chesi M, Nardini E, Brenets LA, Schroek E, Reid T, Kuehl WM, Bergpapel FL. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 1997;16:260-3.


To investigate the origin of the mutation shared by the two affected sibs, inheritance of VNTR alleles on chromosome 4p was studied (fig 2). The affected children had two different maternal haplotypes but shared a paternal 4p haplotype encompassing the $FGFR3$ locus. As the $FGFR3$ g1138a mutation occurs exclusively on paternal chromosomes, and the affected children had two different maternal 4p haplotypes, the most likely explanations for these findings would be either two independent mutational events occurring by chance on the same paternal haplotype, or mosaicism at the spermatogonial level (before meiosis I) in the father. Paternal sperm was not available and the hypothesis of gonadal mosaicism could not be further substantiated.

We conclude that recurrence of achondroplasia in this family was associated with de novo mutational event(s) occurring in the paternal germline, as is the case in sporadic cases, but could not distinguish between paternal gonadal mosaicism or the chance occurrence of two independent mutational events. The apparent rarity of...
somatic mosaicism for FGFR3 mutations in spite of the high mutation rate in achondroplasia remains unexplained.

This work was supported by the Swiss National Foundation (32-57272.99 and 32-42198.94) and the Bonizzi-Theler-Stiftung Zürich.

DIANA SOBETZKO*
SUZANNE BRAGA†
ANDREA SUPERTI-FURGA*

*Division of Metabolic and Molecular Paediatrics, Department of Paediatrics, University of Zürich, University Children's Hospital, Steinwiesestrasse 75, CH-8032 Zürich, Switzerland
†Division of Medical Genetics, Department of Paediatrics, University of Berne, Switzerland

Correspondence to: Dr Superti-Furga, asuperti@access.unizh.ch


Homozgygous deletion of SHOX in a mentally retarded male with Langer mesomelic dysplasia

EDITOR—Langer mesomelic dysplasia (LMD) is a rare skeletal dysplasia characterised by severe short stature owing to shortening and maldevelopment of the mesomelic and rhizomelic segments of the limbs. Associated malformations are rarely reported and intellect is normal in all affected subjects reported to date.1-5 The clinical observation has been made that the parents of subjects with LMD often have short stature, most commonly with the associated clinical and radiographic appearances of Léri-Weill dyschondrosteosis (DC).6 This dominantly transmitted condition is characterised by moderate short stature predominantly because of short mesomelic limb segments. It is often associated with the Madelung deformity of the wrist, comprising bowing of the radius and dorsal dislocation of the distal ulna. This observation has led to the suggestion that LMD is the homozgygous expression of the mutant gene for DC.5-6

Shears et al7 and Belin et al7 recently showed that the molecular defect in DC is mutation within or deletion of the SHOX gene located within the primary pseudautosomal region of the X and Y chromosomes. Deletion or
mutation of SHOX has also been shown to lead to short stature without overt bone dysplasia. Belin et al documented the molecular analysis of a 24 week fetus of a female patient with DC and a pseudoautosomal deletion encompassing SHOX. The fetus had a 45,X karyotype and the radiographic appearances of LMD. They showed that the Xp chromosomal haplotype at the SHOX locus retained by this fetus was the maternal one, encompassing the deleted SHOX gene, rendering the fetus nullizygous for SHOX. Shears et al reported that deletions of SHOX alleles were derived from both parents in a 20 week fetus with radiographic appearances of LMD. These findings in fetuses were the first molecular evidence to support nullizygosity for SHOX as the cause of LMD; however, molecular confirmation in a living patient with LMD has not been previously described.

We present a description of a mentally retarded boy with LMD and his parents, both of whom have DC and normal intellect. Molecular analysis shows that each parent is hemizygously deleted at the SHOX locus and that the proband has inherited both alleles harbouring the deletions, confirming this as the aetiology of LMD.

The patient, a male, was the first born child to non-consanguineous parents both of whom had short stature (fig 1, III.1). He was delivered by caesarean section for fetal distress at 35 weeks’ gestation. He was in good condition immediately after delivery. His birth weight was 1480 g (−2.6 SD), length was 33 cm (−4.3 SD), and OFC was 28 cm (−3 SD). Severe rhizomelic and mesomelic shortening of all four limbs was immediately obvious on delivery and subsequent radiographic findings were consistent with LMD (fig 2). He required gavage feeding for two weeks and developmental progress in the first two years of life was appreciably delayed with expressive language being particularly slow to develop. At review aged 12 years he remained severely mentally retarded. He had no speech, was not toilet trained, and could only assist in dressing by raising his hands and feet. He was ambulatory but walked with a swaying gait and with flexion at the hips to retain balance. In the year before review he had developed generalised seizures which were satisfactorily controlled with valproate. He was 97 cm tall (−7.2 SD) with a weight of 17 kg (−3.6 SD) and OFC of 49.5 cm (−3.0 SD). There was marked rhizomelic and mesomelic shortening of all limbs (fig 3). The hands and feet were of normal size, although there was partial soft tissue syndactyly and camptodactyly of digits 2–5, and clinodactyly of the fifth digits bilaterally in the hands. Both hands showed ulnar deviation at the wrists and both big toes were proximally placed. There were no other anomalies present except for a large gap between the central maxillary incisors and a mild pectus excavatum deformity. There was no mandibular hypoplasia. Pubertal status was Tanner stage 3.
Investigations have included a normal CT scan of the brain at 3 years and an interictal EEG performed at 13 years, which showed no frank epileptiform activity or asymmetry although there was a marked excess of theta activity and no well defined alpha rhythm. Results of a karyotype, fragile X molecular testing, and urine organic acid profile were normal.

The father of the proband (II.4) was 162 cm tall (−2.3 SD) and the mother (II.5) was 145 cm (−2.7 SD). Both parents were of normal intellect. They had short arms and legs, most pronounced in the mesomelic segments. A bilateral wrist deformity was clinically present in both, comprising a subluxation of the distal ulna and resulting in a mild limitation in supination. The mother’s deformity was more pronounced than that of the father. Radiographs showed a Madelung deformity with bowing and thickening of the middle third of the radius (fig 4). The couple’s second pregnancy, a male (III.2), had been terminated in the second trimester owing to detection of severely shortened limbs on ultrasound. No necropsy was performed. A brother of the proband (III.3), aged 6 years, was noted to be of normal intellect, 112.3 cm tall (−0.7 SD), and to have normal body proportions. Multiple members of the extended family exhibited short stature and the same appearance at the wrist although none of them was available for clinical examination. No other member of the extended family has intellectual impairment.

Blood samples were obtained from II.4, II.5, III.1, and III.3, and microsatellite analysis, fluorescence in situ hybridisation (FISH), and Southern blotting were performed to examine the region around the \textit{SHOX} locus. Fluorescent labelled primers were used to amplify the pseudoautosomal microsatellite markers DXYS233, DXYS228, DXYS6814, DXYS230, and the \textit{SHOX} CA repeat in the 5’UTR of \textit{SHOX} exon 1. 7 Microsatellite analysis of the X specific markers DXS7107, DXS1060, DXS1226, DXS1060, DXS1223, DXS987, and DXS1226 was also undertaken.

<table>
<thead>
<tr>
<th>X-specific</th>
<th>PAR1</th>
<th>X</th>
<th>Y</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOX CA</td>
<td>DXYS233</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>DXYS6814</td>
<td>DXYS228</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>DXYS230</td>
<td>DXS7107</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>DXS1060</td>
<td>DXS1223</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>DXS987</td>
<td>DXS1226</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>X-specific</th>
<th>PAR1</th>
<th>X</th>
<th>Y</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHOX CA</td>
<td>DXYS233</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>DXYS6814</td>
<td>DXYS228</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>DXYS230</td>
<td>DXS7107</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>DXS1060</td>
<td>DXS1223</td>
<td>3</td>
<td>1</td>
</tr>
<tr>
<td>DXS987</td>
<td>DXS1226</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

Figure 3  Clinical appearance of the proband, aged 12 years. Rhizomelic and mesomelic limb shortening is present. Syndactyly and camptodactyly is present in the hands. Proximal placement of the big toes is evident.

Figure 4  Radiographic appearance of the forearm of the parents of the proband. (A) Lateral view of the mother’s forearm (II.5) showing dorsal dislocation of the ulna. (B) AP view of the paternal forearm (II.4) showing bowing and thickening of the midshaft of the radius.

Figure 5  (A) Haplotypes of markers on Xp/Yp showing the maternal deletion and compatible with a paternal deletion. The obligate crossover in male meiosis is seen. (B) PCR of \textit{SHOX} exon 2 (band at 517 bp) showing that no PCR product was obtained with DNA from the proband (III.1). No PCR product was obtained in the proband for any of the \textit{SHOX} exons or for the \textit{SHOX} CA repeat (data not shown). The lower panel shows that PCR product is obtained in the proband with control primers at the locus DXS230 (band between 220 bp and 298 bp).
Results showed that the proband (III.1) did not inherit an allele at the DXYS233 locus from his mother (II.5), indicating a maternal PAR1 deletion (fig 5A). A paternally derived allele at DXYS233 was present. No PCR product was obtained with the proband’s DNA for the SHOX CA repeat, and the parents could both be either hemizygous or homozygous at this locus. In addition, since the proband’s DNA failed to amplify with primers for each exon of SHOX (fig 5B), we concluded that there was a homozygous deletion encompassing SHOX in the proband. Heterozygosity in the proband for the more proximal PAR1 microsatellite markers DXYS6814, DXYS228, and DXYS230 indicates that neither deletion extends into the X specific region, but both are confined to the pseudoautosomal region. The normal brother of the proband (III.3) has inherited the opposite maternal and paternal haplotypes to the proband.

FISH was performed on metaphase spreads of lymphocytes obtained from whole blood or from transformed lymphoblastoid lines.11 Cosmid LLNOYCO3'M'34F5, which contains SHOX exons 1-5b, was obtained from the Lawrence Livermore Y chromosome specific library and was labelled by nick translation with biotin-16 dUTP (Gibco BRL BioNick Labeling System). A total of 15 metaphases were analysed using a Leitz DMLB fluorescence microscope and images were captured and stored using Applied Imaging software. A homozygous deletion of SHOX was shown in the mother (fig 6A). However, in the father, signals were visible on both the X and Y chromosomes (fig 6B) and in the proband an X chromosome deletion was present but there was a signal on the Y (fig 6C). We therefore performed Southern blotting to show the paternally derived SHOX deletion.

A Southern blot of HindIII digested genomic DNA of II.4, II.5, III.1, and III.3 was hybridised with a probe for SHOX exons 3 to 4. The blot was then stripped and rehybridised with a dosage control probe from chromosome 22 (TBX1, IMAGE cDNA clone 1876034). Probe labelling and detection was performed using the Gene Images™ system (Amersham). There was no signal with the SHOX probe in the proband, III.1 (upper panel, fig 7), but the dosage control probe signal was present (lower panel, fig 7), confirming that the proband is homozygously deleted for SHOX. A dosage effect was shown with the SHOX probe in the parents of the proband, II.4 and II.5. These lanes both showed a weaker intensity signal than the normal sib, III.3. The dosage control probe showed equal signals in all lanes indicating that the parents are hemizygously deleted for SHOX.

A variety of dominantly transmitted disorders, such as achondroplasia, aniridia, and Waardenburg syndrome, express a more severe phenotype when present in the homozygous form.12 Langer mesomelic dysplasia has long been considered the homozygous expression of DC on purely clinical grounds, but until the demonstration of the molecular defect underlying the disorder, definitive evidence has been lacking. This report is the first confirmation in a living patient that nullizygosity for SHOX causes LMD. Both parents had the clinical and radiographic appearances of DC and both harboured heterozygous deletions of one SHOX allele.
The SHOX gene is located within the primary pseudoautosomal region (PAR1) at the telomere of the short arm of the X and Y chromosomes. This region escapes X inactivation in females and participates in obligate recombination during male meiosis. Consequently, DC segregates as an apparently "autosomal" dominant trait. Recombination during male meiosis. Consequently, escapes X inactivation in females and participates in obligate recombination in the pseudoautosomal region (PAR1) at the telomere of the SHOX alleles, the paternal Y chromosome having undergone meiotic recombination with a breakpoint centromeric to the SHOX locus. The obligation requirement for crossing over in PAR1 may predispose to a higher rate of mispairing with resultant deletions in this very localised chromosomal region. An accurate estimation of the frequency of such events is difficult since it is likely that DC is underdiagnosed within the general population owing to the wide clinical spectrum. Analysis of the small number of patients with DC examined with molecular methods so far has indicated that deletion is a common mode of mutation in this disorder. The studies of Shears et al. and Belin et al. showed that 12 out of 14 cases were the result of deletions encompassing the SHOX locus, the remaining two being point mutations.

It is interesting to note that there are no previous reports of an association of mental retardation with LMD, although it has been described previously in association with DC. Shears et al. noted minor dysmorphic features and learning disabilities in a pair of female monozygotic twins with DC. They postulated that this might be explained by deletion of contiguous genes; however, in this case the responsible deletion encompassing the SHOX locus extended into the X specific region and was large enough to be visible on G banding. Spranger et al. reported a mother-son pair with DC, the son manifesting in addition mental retardation, myoclonic epilepsy, and chondrodysplasia punctata. Molecular mapping studies showed the extent of the maternally derived deletion to include not only SHOX, but also ARSE, the gene mutated in X linked chondrodysplasia punctata, and the putative mental retardation locus MRX49. The normal intelligence and seizure free status of the mother suggests that the phenotype of her son was attributable to heterozygosity for the SHOX deletion in addition to nullizygosity for ARSE and possibly MRX49. Thus in both these cases the deletion extended well into the X specific region and could include established MRX loci. Microsatellite and cytogenetic analysis of the deletions in the present case have indicated that the maternal deletion is more extensive than the paternal deletion, but is still confined within PAR1 and does not extend into the X specific region. Several MRX loci map close to PAR1, but to our knowledge one or both of the deletions do not encompass the putative MRXY locus. They could also carry one or more point mutations which would not be expected to cause mental retardation.

The study of this patient shows that nullizygosity for SHOX causes Langer mesomelic dysplasia and confirms it as the homozygous form of Léri-Weill dyschondrosteosis. The association of LMD with mental retardation in this patient also suggests the existence of a recessively acting pseudoautosomal mental retardation locus.

The first two authors contributed equally to this work. We thank the family for their assistance with this study. DJS is supported by a Research Training Fellowship from the Wellcome Trust, ref 051419/055.

STEPHEN P ROBERTSON†
DEBORAH J SHEARS‡
ROBIN M WINTER†
PAUL OEE‡
SALIM AFTIMOS§
RAVI SAVARIRAYAN‡

* Victorian Clinical Genetics Service, Royal Children’s Hospital, Parkville, Victoria, Australia
† Institute of Child Health, London, UK
§ Cytogenetics Laboratory, Starship Children’s Hospital, Auckland, New Zealand
¶ Northern Regional Genetics Service, Auckland, New Zealand

Dr Robertson, The Institute of Molecular Medicine, The John Radcliffe, Headington, Oxford OX3 9DS, UK, steve.robertson@imm.ox.ac.uk

Tandem triplication of chromosome 13q14 with inverted interstitial segment in a 4 year old girl

Editor—Application of chromosome painting has enabled confirmation that an additional segment in a presumed tandem duplication originates from the rearranged chromosome. More recent studies to determine more accurately the exact amount of duplication with cosmid FISH probes have, in a few instances, shown that some of the presumed duplications were in fact triplications of smaller segments. In some of these patients, unequal distances between the FISH signals showed that the middle segment of the tandemly arrayed three segments was in the opposite orientation. Unequal distance between three pairs of signals, with the first two in a row being very close, but both 1


Figure 1 The proband aged 4 years. Note deep set eyes with upward slanting palpebral fissures and bulbous tip of nose.
being quite far apart from the third pair of signals, indicates a distal location of the RB1 gene within band 13q14 (fig 2). FISH and DAPI banding (=850 bands/karyotype) placed the RB1 locus at 13q14.2. Combining the pattern of GTG bands with the results of DAPI banding, the proximal breakpoint appears to be very distally located in 13q13.3, while the distal breakpoint appears to be very proximally located in 13q21.1 (fig 2).

The patient’s karyotype can be described as: 46,XX,t[trp(13)(q14q14)de novo.fish trp(13)(pter→q21.1::q21.1→q13.3::q13.3→qter)(D13S118+++, RB1+++, D13S19++++, D13S25+++). The results of microsatellite polymorphism analysis are shown in table 1. Two of the 12 loci showed inheritance of one maternal and two paternal alleles. Locus D13S284, which maps to 13q14.3, displayed three distinct alleles, two being paternal in origin (fig 3). At locus D13S155, which maps to 13q14.3-q21.2, the paternal band was clearly stronger than the maternal band. At locus D13S263, which maps to 13q14.1-q14.2, the paternal band was possibly stronger than the maternal one (data not shown). Normal biparental inheritance of loci proximal (D13S221) and distal (D13S170, D13S173) to 13q14 was seen. These results indicate that the triplication of 13q14 was paternal in origin and that both paternal chromosomes 13 were involved in its formation.

Clinical observations suggest that, in general, tetrasomy of an autosomal segment causes a similar, but more severe clinical picture than trisomy of the same segment. This has been shown, for example, for 9p, 18p, and 15(q12-q13). Further, for some segments (8p, 12p) tetrasomy is viable only in a mosaic state while trisomy without mosaicism is compatible with survival. No other patients with tetrasomy for segment 13q14 are yet known. Trisomy of this segment was only detected following cytogenetic investigation of families with several members affected with retinoblastoma; unbalanced familial insertional translocations resulting in 13q14 deletion caused retinoblastoma while those resulting in 13q14 duplication caused a very mild clinical phenotype or even no anomalies. The patients were described as either having “no definite clinical syndrome,” being normal, or normal with short stature. Thus, the mild but still distinct phenotype of our proband with triplication as compared to the above mentioned cases with duplication of 13q14 is in accordance with the previous observations with other chromosomal segments. Duplication of a larger segment (13q12-q22) including 13q14 was also found in family investigations because of familial occurrence of retinoblastoma.

Not unexpectedly because of the larger size of the duplication, these patients showed mild dysmorphism and mild to moderate mental retardation. Patients with a proximal duplication, dup(13)(pter-q14q21), show a non-specific pattern of mostly minor anomalies and moderate mental retardation, while patients with a distal 13q duplication including 13q14, for example, dup(13)(q14→qter), show multiple congenital anomalies including postaxial polydactyly and profound mental retardation. Tetrasomy of (13)(q14.3→q22), that is, most of segment 13q21, in combination with duplications of the adjacent proximal (13q14.1-q14.3) and distal (13q22-qter) seg-

Table 1

<table>
<thead>
<tr>
<th>Marker</th>
<th>Patient</th>
<th>Mother</th>
<th>Father</th>
<th>Genetic distance*</th>
</tr>
</thead>
<tbody>
<tr>
<td>D13S221</td>
<td>bc</td>
<td>bc</td>
<td>ab</td>
<td>—</td>
</tr>
<tr>
<td>D13S218</td>
<td>ac</td>
<td>ac</td>
<td>bc</td>
<td>29 cM</td>
</tr>
<tr>
<td>D13S263</td>
<td>ab(b?)</td>
<td>aa</td>
<td>ab</td>
<td>3 cM</td>
</tr>
<tr>
<td>D13S118</td>
<td>ab</td>
<td>bb</td>
<td>aa</td>
<td>0.6 cM</td>
</tr>
<tr>
<td>D13S153</td>
<td>ab</td>
<td>ab</td>
<td>ab</td>
<td>0 cM</td>
</tr>
<tr>
<td>D13S137</td>
<td>bb</td>
<td>ab</td>
<td>ab</td>
<td>0 cM</td>
</tr>
<tr>
<td>D13S155</td>
<td>abb</td>
<td>aa</td>
<td>bb</td>
<td>0 cM</td>
</tr>
<tr>
<td>D13S284</td>
<td>bcd</td>
<td>ab</td>
<td>cd</td>
<td>0.7 cM</td>
</tr>
<tr>
<td>D13S124</td>
<td>ac</td>
<td>cc</td>
<td>ab</td>
<td>12 cM</td>
</tr>
<tr>
<td>D13S162</td>
<td>bc</td>
<td>bd</td>
<td>ac</td>
<td>5.7 cM</td>
</tr>
<tr>
<td>D13S170</td>
<td>bb</td>
<td>bc</td>
<td>ab</td>
<td>30 cM</td>
</tr>
<tr>
<td>D13S173</td>
<td>bb</td>
<td>bb</td>
<td>ab</td>
<td>—</td>
</tr>
</tbody>
</table>

*Approximate genetic distances according to Généthon and LDB linkage maps.
ments was determined in a newborn girl with a complex de novo rearrangement. The proband died shortly after birth with multiple major malformations including a malformation of the brain stem, cerebellar hypoplasia, cloudy corneae, aniridia, microphthalmia and other ocular anomalies, intestinal malrotation, cystic horseshoe kidneys, patent urachus, polydactyly of the fingers and toes, and many others. In this case, it is impossible to attribute single anomalies to duplication versus triplication of specific 13q segments present in a hyperdiploid state.

While direct or inverted tandem duplications could be formed through unequal crossover or unequal sister chromatric exchanges,18 triplications of this kind require a more complex mechanism of origin. For a case of triplication of 15q11-q13, meiotic recombination between an inv dup(15)(q13) chromosome and a normal 15 with subsequent loss of the marker was proposed.1 A similar mechanism has also been proposed to explain amplification of the dihydrofolate reductase (DHFR) gene in Chinese hamster cells. Another possible mechanism would be that the parent from whom the aberration stems (in our case the father) would either carry a constitutional paracentric inversion of the triplicated segment or such an inversion would be formed in a prezygotic cell. Although banded chromosome examinations of the father of our proband yielded normal results, a paracentric inversion of just 13q14 could not be excluded unless bicolour FISH studies were performed, which in this case was not possible. Two crossovers within the inversion loop with a U-type exchange would result in a tandem triplication with an inverted middle segment.

This type of triplication has so far been reported for the following chromosomal segments: 2q11.2-q21,2 4q37,2 5p14-p15.33,3 7p21.2-p21.3,4 9p13-p22,5 10q26,6 13q14 (present report), and 15q11-q13.19,20 It is interesting to note that in several cases an unequal distance between two FISH signals (the proximal and the middle versus the middle and the distal) indicated that either the middle segment was inverted or, less likely, the middle segment was in normal orientation, but the proximal and distal segments were inverted,1,4,6 probably, according to the illustrations, the cases of Rauch et al12 and Harrison et al13 and the present report. In the other patients, no special attention was paid to the issue of direct versus inverted triplication. In the case of direct orientation of all three segments, the distances between the signals should be of equal length; however, even in the case of an inverted middle segment, the distances would only be of equal length if the FISH probes map to the middle of the triplicated segment at equal distances from the two ends.

It is likely that a proportion of cases of segmental triplication are incorrectly interpreted as duplication while in fact there is triplication of a smaller segment. This could also account for part of the phenotypic variability observed between such patients with presumed similar phenotypes, especially with respect to interstitial segments for which there are few familial insertional translocations and thus proven instances of duplication. Banded chromosome analysis alone will in very few cases allow discrimination between duplication and triplication. We therefore propose that FISH studies using probes mapping to the presumed duplicated segment should constitute part of the diagnostic work up following determination of a tandem duplication through banded chromosome examination and chromosome painting with whole chromosome probes.

The authors thank Drs P Lichter and S Stilgenbauer for YACs from the 13q14 segment. The investigation was supported by the Swiss National Foundation, grant Nos 32-45004.95 and 32-37798.93.

LUKREICJA BREVECIVIC* SEHER BASARAN† FABRIZIO DUTLY* BENNO ROTHLSBERGER‡ ALBERT SCHINZEL* †Institute of Medical Genetics, University of Zürich, Rämistrasse 74, CH-8001 Zürich, Switzerland
‡Department of Paediatrics, University of Istanbul, Istanbul, Turkey
Correspondence to: Professor Schinzel, schinzel@medgen.unizh.ch

The first three mosaic cri du chat syndrome patients with two rearranged cell lines

EDITOR—Cri du chat syndrome (CdCS) is one of the more common deletion syndromes, involving the short arm of chromosome 5, with an incidence of 1 in 50 000 live births. Classically, patients with this syndrome present with microcephaly, a round face, hypertelorism, micrognathia, prominent nasal bridge, epicanthic folds, hypotonia, and severe psychomotor retardation. Infants also exhibit a high pitched cry similar to the mewing of a cat, which is usually considered diagnostic for this syndrome.

Recently, genotype-phenotype studies in CdCS led to the identification of two separate chromosomal regions, hemizygosity for which is associated with specific phenotypes. A deletion of 5p15.3 results in the manifestation of a cat-like cry, while a deletion of 5p15.2 results in the presentation of the other major clinical features of the syndrome. Moreover, a region for speech delay in 5p15.3 has been identified.

From a review of 331 published cases, Niebuhr estimated that most CdCS cases are the result of de novo deletions (about 80%), some derive from a familial rearrangement (12%), and only a few show other rare cytogenetic aberrations, such as mosaicism (3%), rings (2.4%), and de novo translocations (3%). Chromosomal mosaicism in CdCS has been described involving a cell line with a 5p deletion and a cell line with a normal karyotype. 5

We describe the first three reported cases of mosaic de novo 5p anomalies involving two rearranged cell lines in CdCS out of 80 (3.75%) patients from the Italian Register of CdCS analysed in a large study of correlation between 5p deletion and phenotypic effect (Cerruti Mainardi et al, manuscript in preparation).

Patient 1 was the first female child of healthy, unrelated parents. At birth the mother was 29 and the father 31 years old. The pregnancy was complicated by a threatened miscarriage in the 12th week of gestation. There had been no exposure to alcohol, nicotine, drugs, x-rays, or teratogens during pregnancy. Her younger sister was healthy. The family history was unremarkable.

The baby was born by caesarean section because of reduced uterine contractions in the 39th week of gestation. Apgar scores were 7 and 6 at one and five minutes, respectively. Her birth weight was 2750 g (10th-25th centile), length was 48 cm (25th centile), and head circumference was 34 cm (25th-50th centile).

The neonatal course was complicated by transient respiratory distress and metabolic acidosis. In the first days of life, sucking difficulties were reported, requiring nasogastric feeding. Neonatal physical examination showed epicanthic folds and hypertelorism. CdCS was suspected because of an abnormal cry and was confirmed by cytogenetic analysis. No significant medical illness was observed during infancy.

On physical examination at the age of 6 years, weight was 20.7 kg (50th centile), height was 114.5 cm (50th centile), and head circumference was 49 cm (3rd-10th centile). Clinical features included a high voice, downward slanting palpebral fissures, broad nasal bridge, hypertelorism, epicanthic folds, slight micrognathia, slightly low set ears, diastasis recti, and flat arches of the feet. Dysmorphism was felt to be mild (fig 1A).

However, developmental delay, evaluated with the Denver Developmental Screening Tests, was present: she sat with her head steady at 6 months, sat without support at 10 months, and walked well at 2 years. Speech delay was more severe; she spoke her first words at 4 years and could combine two different words at 6 years.

Chromosome analysis of the patient, performed on peripheral blood lymphocytes, showed two cell lines; in 73% of cells a 5p deletion was observed and in 27% of cells a 5p duplication was observed.

FISH analysis performed with specific single locus DNA lambda phage probes spanning 5p identified breakpoints both on the deleted chromosome 5 and on the duplicated one. The breakpoint on the deleted chromosome 5 is in p14.1 between D5S769 and D5S711 and the breakpoints on the duplicated chromosome 5 are in p15.2 between D5S778 and D5S751 and in p12 between D5S802 and the centromere. The duplication is inverted.

The cytogenetic and FISH results are summarised in fig 1B and C. In conclusion the karyotype was interpreted as: 46,XX,del(5)(p14.1→qter)(D5S711-)[73]/46,XX,ish dup(5)(p12→p15.2::p15.2→qter)(D5S802++, D5S778 +++, D5S751-)[27]. The parents’ and sister’s karyotypes were normal.

Molecular analysis performed with microsatellite D5S214 indicated the paternal origin of the deleted and the duplicated chromosomes 5.

Patient 2 was the second female child of healthy, unrelated parents. At birth the mother was 26 and the father 31 years old. Pregnancy was complicated by bleeding in the first 12 weeks; ultrasound examination showed intrauterine growth retardation. There was exposure to nicotine during pregnancy (15 cigarettes a day). The family history was remarkable for two deaf maternal aunts.

The baby was delivered in the 40th week of gestation. Her birth weight was 2680 g (3rd-10th centile); length and head circumference were not recorded. The neonatal course was complicated by metabolic acidosis. Cytogenetic analysis, performed in another laboratory because of dysmorphism, showed a karyotype with three cell lines: 46,XX,del(5)(p15)[65]/46,XX[33]/46,XX,dup(5)(p13→qter) [2].
During infancy, she suffered from recurrent bronchial and pulmonary infections requiring admission to hospital. There was an episode of seizures and psychomotor development, evaluated with Denver Developmental Screening Tests, was delayed; she was able to sit at 1 year and to walk and speak her first words at 4 years.

Physical examination at 5 years showed weight 18.5 kg (50th centile), height 104 cm (10th-25th centile), and head circumference 47 cm (<3rd centile). Clinical features included a high voice, broad nasal bridge, hypertelorism, epicanthic folds, myopia and mild convergent strabismus, downturned corners of the mouth, micrognathia, low set ears, left preauricular tag, transverse flexion creases, clinodactyly, diastasis recti, flat arches of the feet, and anteriorly placed anus (fig 2A). She showed severe mental and speech delay and hyperactive behaviour.

Chromosome analysis of the patient, performed on peripheral blood lymphocytes, showed two cell lines; in 76% of cells a 5p deletion was observed and in 24% of cells a chromosome 5 with normal dimensions and banding pattern was observed.

FISH analysis performed with specific single locus DNA lambda phage probes spanning 5p established that the apparently normal chromosome 5 really represented a 5p duplication and identified breakpoints both on the deleted and the duplicated chromosomes 5. The breakpoint on the deleted chromosome 5 is in p14.3 between D5S25 and D5S28 and the breakpoints on the duplicated chromosome 5 are in p14.3 between D5S25 and D5S28 and in p12 between D5S802 and the centromere. The duplication is inverted.

The cytogenetic and FISH results are summarised in fig 2B and C. In conclusion the karyotype was interpreted as: 46,XX, ish del(5)(p14.3→qter)(D5S28−)[76]/46,XX,ish dup(5)(p12→p14.3::p14.3→qter)(D5S802++,D5S25++,D5S28−)[24]. The parents’ karyotypes were normal.

Molecular analysis performed with microsatellite DSS1981 indicated the paternal origin of the deleted chromosome 5.

Patient 3 was the first female child of healthy, unrelated parents. At birth the mother was 30 and the father 33. The pregnancy was uneventful and there was no exposure to alcohol, nicotine, drugs, x rays, or teratogens during pregnancy. Her younger sister and brother were healthy. The family history was unremarkable.
The baby was delivered at 40 weeks of gestation. Her birth weight was 2600 g (3rd -10th centile), length was 50 cm (50th-75th centile), and head circumference was 33 cm (10th-25th centile). CdCS was suspected because of dysmorphism, microcephaly, and a high pitched monotonous cry and was confirmed by cytogenetic analysis. Talipes of the left foot was observed.

At the ages of 3½ and 5½ she underwent two operations for left cholesteatoma. During infancy her psychomotor development, evaluated with Denver Developmental Screening Tests, was delayed; she was able to grasp objects at 8 months, to sit at 2 years, to say her first words at 3 years, and to walk at 3½ years. Menarche occurred at 11 years.

On physical examination at 12 years, her weight was 40 kg (50th centile), height was 137 cm (<3rd centile), and head circumference was 48 cm (<3rd centile). Clinical features included a high voice, epicanthic folds, divergent strabismus, micrognathia, a high arched palate, slightly low set ears, incomplete bilateral flexion creases, diastasis recti, flat arches of the feet, and talipes of the left foot (fig 3A). She showed severe mental and speech delay and hyperactive behaviour.

Chromosome analysis of the patient, performed on peripheral blood lymphocytes, showed two cell lines with the following deletions: in 78% of cells the deletion extended from pter to p13 and in 22% of cells the deletion extended from pter to p14.3.

FISH analysis performed with specific single locus DNA lambda phage probes spanning 5p allowed finer definition of the extent of the deletions. The breakpoint on the more deleted chromosome 5 is in p13 between D5S743 and D5S787 and the breakpoint on the less deleted chromosome 5 is in p14.3 between D5S699 and D5S796. The cytogenetic and FISH results are summarised in fig 3B and C.

In conclusion, the karyotype was interpreted as: 46,XX,ish del(5)(pter→q13)(D5S787–)[78]/46,XX,ish del(5)(pter→q14.3)(D5S796–)[22]. The parents' karyotypes were normal. Molecular analysis performed with microsatellite D5S198711 indicated the maternal origin of the deleted chromosome 5.

In summary, as a consequence of these rearrangements of chromosome 5p, at least in peripheral blood lymphocytes, patients 1 and 2 have a partial monosomic cell line and a partial monosomic/trisomic cell line, while patient 3 shows two different partial monosomies.

It is interesting to analyse the CdCS phenotype of patients 1 and 2 in relation to the presence of partial trisomy 5p in a proportion of cells. Partial trisomy 5p was first described in 1964, but it is a very rare event. Most partial trisomies 5p are the consequence of an unbalanced

![Figure 2](A) Case 2 at 5 years. (B) Ideogram of the normal and the abnormal chromosomes 5 in both cell lines. Specific single locus probes used to define breakpoints are shown. (C) FISH performed with DSS763 lambda phage probe shows a duplication on one chromosome 5.
translocation with another autosome. However, although some manifestations may differ from case to case because of the effect of the monosomy of the other chromosome involved in the translocation, a clinically recognisable and consistent phenotype is always present and is apparently little influenced by the presence of concomitant autosomal imbalance. The most common manifestations are normal birth weight, macrodolichocephaly, downward slanting palpebral fissures, epicanthus, bulbous nose, low set ears, short big toes, hypotonia, seizures, and psychomotor retardation. Multiple congenital anomalies are present and early death is frequent.13–19 The extent of the clinical findings in the reported cases depends on the length of the trisomic portion. The larger the trisomy, the more pronounced are the clinical signs. Physical signs are almost absent when 5p14-ter is involved, while those cases with trisomies of chromosome material including 5p13 or the complete short arm have more severe multiple congenital anomalies, mental retardation, and growth failure.20 Signs and malformations described in patients with partial monosomy 5p and in patients with partial trisomy 5p compared to those observed in patients 1 and 2 are summarised in table 1.

Of particular interest are the mild phenotype in patient 1 and the comparison between patients 1 and 2 (figs 1A and 2A). From the developmental point of view, the two patients are comparable since they are approximately the same age, the parents’ educational levels are similar, and they followed the same therapeutic programme with the same person. Patient 1 shows a CdCS phenotype with the cat-like cry, dysmorphism, and developmental and speech delay. However, her phenotype is very mild in relation to the deletion breakpoint in 5p14.1 (D5S711), especially when compared with the results obtained from a wider study on CdCS (Cerruti Mainardi et al, manuscript in preparation). The large duplication of 5p12-5p15.2 apparently does not produce any significant phenotypic effect. This is in contrast to patients with duplication of 5p. Patient 2 shows a severe CdCS phenotype in relation to the deletion breakpoint in 5p14.3 (D5S28). Some clinical features and malformations are attributable to partial trisomy 5p and others are common both to partial monosomy and partial trisomy 5p (table 1).

The phenotype of patient 1 is milder than patient 2, although the deletion is bigger. We therefore speculate that in patient 1, 5p deletion and 5p duplication could compensate for each other with the duplicated cell line contributing a double dosage of the critical region in 5p15.2, while the cat-like cry and the speech delay regions are present in single dose (fig 1B). This compensation is not possible in patient 2, where the region between 5p14.3 and the telomere is deleted in both cell lines (fig 2B). Overall, in both cases the CdCS phenotype prevails.

The cell line with the deletion is more prevalent compared with that with the duplication, at least in periph-

Figure 3  (A) Case 3 at 12 years. (B) Ideogram of the normal and the abnormal chromosomes 5 in both cell lines. Specific single locus probes used to define breakpoints are reported. (C) FISH performed with D5S763 lambda phage probe shows two different deletions in the two adjacent metaphases; in the upper one the probe is not deleted, while in the lower it is deleted (arrows).
eral blood lymphocytes. This would suggest that the deletion has been favoured during development because monosomy 5p is less severe than trisomy 5p, as supported by the fact that monosomy 5p is far more common than trisomy 5p.

Patient 3, where both cell lines have a deletion (fig 3B), shows a classical CdCS phenotype (fig 3A) and its severity could be because of the prevalence of the more deleted cell line.

We report a frequency of mosaicism in CdCS of 3.75%. To the best of our knowledge, this is the largest record of cases of de novo 5p anomalies involving two rearranged cell lines, and provide new insights into mosaic structural rearrangements and into genotype-phenotype correlations in CdCS.

recognition within a single chromatid, and excision of intrachromatid loops may result from the presence of repeated sequences in the human genome.\(^{29-35}\)

The absence of a normal cell line in all three cases presented here is consistent with a prezygotic origin of inverted tandem duplication. Different mechanisms have been proposed to explain the origin of such duplications.\(^{29-35}\) In these cases, the explanation is complicated by the presence of mosaicism and by the absence of preferential breakpoints. We could postulate that, in all cases, the first common event is the formation of a dicentric chromosome by recombination between mipsaid copies of repeated and inversely oriented sequences at meiosis I; then, at anaphase I, a breakage of the resulting dicentric isochromosome would cause, respectively, the invdup(5p) in patients 1 and 2 and a del(5p) in patient 3. Mosaicism could then arise mitotically at the level of a single DNA strand where loop formation and unequal crossing over between repeated sequences could cause breakage of the strand at different points and generate the deleted cell line in patients 1 and 2 and the line with a bigger deletion in patient 3.

In conclusion, these patients represent the first three cases of de novo 5p anomalies involving two rearranged cell lines, and provide new insights into mosaic structural rearrangements and into genotype-phenotype correlations in CdCS.

Abnormal sex differentiation and multiple congenital abnormalities in a subject harbouring an apparently balanced (6;8) translocation

EDITOR—In XY subjects, the tests are influenced by the activity of the sex determining region Y (SRY) gene and its abnormal function usually results in various degrees of sex reversal. However, as suggested by several authors, abnormal sexual development may also be caused by errors in genes located on either the X chromosome (the dosage sensitive sex reversal locus (DSS) at Xp21.3) or autosomes. A few reports also describe abnormal sex development in male patients presenting with 6q chromosome rearrangements, but a more precise localisation at this level of a gene involved in sex determination has not been done.

The present report describes a 46,XY subject of Algerian origin, presenting with complete gonadal failure, abnormal external genitalia, and multiple congenital abnormalities. At birth, bilateral undescended testes, glandular hypospadia, and hypoplastic penes were noted. However, owing to sociocultural conditions, no investigations were performed until the age of 34 years, when he was assessed for infertility and learning disability. His pheno-type included several dysmorphic features: squint, full lips, broad nasal root, large and low set ears, mildly short neck, gynaecomastia, widely spaced nipples, dorsal and lumbar scoliosis, and renal oroveed morphology. The external genitalia were hypoplastic and no gonads were found in the scro-mum. However, the patient presented with post-androgen therapy virilisation, including sparse pubic and facial hair. X ray examination of the skeleton showed L5-S1 vertebral fusion and bilateral lysis of the vertebral isthmus, increased lumbar vertebral canal, and bilateral 4-5 brachymetacar-pus. Ophthalmological examination showed considerable reduction in visual acuity (6/10 on the right side and 3/10 on the left side), amblyopia, divergent strabismus, and visual field loss with right central scotoma. Abdominal ultrasound examination failed to identify any structure that might be interpreted as a gonad. Endocrinological investigation showed complete absence of testicular function: plasma testosterone was 0.57 ng/ml (normal 3.4-9 ng/ml) with no response to HCG stimulation, plasma FSH was 67.5 mIU/ml (normal 1-5 mIU/ml) and plasma LH was 19 mIU/ml (normal 0.8-4 mIU/ml). After administration of

Figure 1 Histological section through the left inguinal structure showing anarchic epididymal tissue surrounded by a small amount of fibrous cells. Microscopic magnification × 4 (A) and × 40 (B).
LHRH (0.1 mg/m²) FSH rose to 194 mIU/ml and LH to 63.1 mIU/ml. The other plasma hormonal levels, including oestradiol, prolactin, cortisol, ACTH, TSH, DHT, 17-OH-progesterone, and D-4-androstenedione, were within the normal range. Calcium binding protein and alkaline phosphatase were also normal.

Laparoscopy was performed and a gonad-like structure was identified and removed from the left inguinal canal. However, no such structure was found on the right side. The patient had a post-appendectomy scar in the right lower abdominal quadrant, suggesting that the gonad might have been removed during the surgical procedure. Histology of the left inguinal structure (fig 1) showed hypo plastic deferent and spermatic cords together with a thin albuginea and a structurally anarchic epididymis-like tube surrounded by a small amount of fibrous cells. The structure did not contain any specific differentiated or undifferentiated testicular tissue.

Cytogenetic analysis using RHG, GTG, GTBG, and RTBG banding showed a homogeneous 46,XYt(6;8)(q27;q13.2) chromosomal complement (fig 2A, B, and C). No microdeletion or microduplication could be identified at either breakpoint level. A count of 20 QFQ banded metaphases showed a normally fluorescent Y chromosome. The parents, of Algerian origin, were not available for investigation. Fluorescence in situ hybridisation (FISH) performed using chromosome 6 and 8 paints (ONCOR) confirmed the balanced translocation (data not shown). To position the distal breakpoint at 6q27 more closely, a FISH technique was performed, using a TATA binding factor gene specific probe (ONCOR) that gave a signal close to the breakpoint on the derivative chromosome 8 (fig 2D).

Southern blot and SSCP analysis of the SRY gene in the subject were found to be identical to that of a normal male and hybridisation with the DXS319 probe, which maps to the distal portion of the DSS locus at Xp21.3, indicated that he carried a single copy of this region (data not shown). Therefore, abnormalities of either of these loci could be excluded as a cause of the patient’s phenotype.

To date, a few reports have described abnormal sex development in 46,XY males with partial deletion of terminal 6q. In 1975, Milosevic and Kalicanin reported a 46,XY subject presenting with growth and mental retardation, microcephaly, dysmorphism including hypertelorism, a broad nasal root, malformed ears, micrognathia, multicystic kidney, bone abnormalities, and bilateral cryptorchidism. The patient had a de novo chromosomal rearrangement resulting in 6q25-6qter deletion. The same cytogenetic abnormality with a similar phenotype was reported by Baroshesky et al. Most of these cases also presented with abnormalities of the kidney and Turner-like phenotype (short stature, cervical cystic hygroma, short neck, and widely spaced nipples). Interestingly, deletions of the long arm of chromosome 6 proximal to band 6q25 do not seem to result in either kidney, genital, or Turner-like anomalies. In our patient, gonadal failure was diagnosed by ultrasound and endocrinological studies, which also excluded pituitary gonadotrophin deficiency, abnormalities of the androgen receptor, or a block in testosterone synthesis. In 1987, Fonatsch et al assigned the TCP1 locus to band 6q25–q27. This gene is the human homologue of the mouse Tcp-1 locus, which is part of the mouse t complex and codes for a protein abundantly expressed in testicular germ cells. Another testis expressed gene, TCP10, which is genetically linked to the oestrogen receptor locus, has been assigned to the same region. Experimental knock-out mice for the Tcp-1 and Tcp-10 loci show abnormal testis development and are sterile. In our patient, the 6q breakpoint was shown to be located at 6q27, proximal to the TATA binding factor gene. The human homologue (T) of the mouse T (Brachyury) gene has also been located in this region. In vertebrates, the protein product of the T gene is a transcription factor crucial for the formation of the normal mesoderm. T mutant Brachyury mice die in mid gestation with severe defects in posterior mesoderm tissues. Heterozygous mice are viable but have posterior axial malformations. T protein has been shown to be associated with the mouse t haplotype, a variant form of the t complex characterised by transmission ratio distortion, male sterility, and recombination suppression. In humans, the T protein is involved in susceptibility to spina bifida, a multifactorial
neural tube defect. Morrison et al. showed that the human T gene maps to 6q27 and lies between the two other genes of the T complex, TCP1 and TCP10.

The present report suggests that male sex determination and differentiation is a complex process, involving several autosomal loci, and at least one of them is possibly located at 6q27.

Distal trisomy 2p and arachnodactyly

EDITOR—We report two sibs with an unbalanced translocation of chromosomes 2 and 10 resulting in distal 2p trisomy. We feel that this sib pair could help to delineate the common features that may result from duplication of this specific region, in particular to show that arachnodactyly is a key feature. We suggest that the combination of arachnodactyly with developmental delay should prompt investigation of this region within the differential diagnosis.

This sib pair was first seen in 1995 aged 8 years (male) and 11 years (female). They were referred with a combination of speech and language delay, poor coordination, and concordant dysmorphic features.

The male sib (fig 1) was born at 38 weeks’ gestation weighing 3200 g (25th centile). He was noted to have gross motor delay with hypotonia and walked at 22 months. He weighed 3200 g (25th centile). He was noted to have gross motor delay with hypotonia and walked at 22 months. He continues to require considerable supplemental educational input and speech therapy. His motor development is still delayed and at the age of 11, he cannot ride a bicycle, catch a ball, or fasten shoe laces. He requires an orthotic appliance because of hallux valgus and requires considerable physical therapy.

His height has followed the 90th centile with weight at the 50th. There is no limb or body segment disproportion. Joint flexibility is normal. He has arachnodactyly (palm length 10.5 cm (75th centile), middle finger length 8.0 cm (97th centile), middle finger to total hand ratio 43%) with fifth finger clinodactyly and prominent finger pads. His feet (fig 2) are narrow with metatarsus varus, medial deviation of the second toe, and a wide sandal gap.

His face is long and triangular with semilunar palpebral fissures (length 2.8 cm). There is a bulbous tip to the nose with a high bridge. The palate is high and arched.

**Figure 1** Male sib aged 8 years showing facial dysmorphism and arachnodactyly.
Ophthalmological examination showed unilateral myopia only. Hearing is normal. Echocardiography is normal.

His sister (fig 3) was born at 38 weeks' gestation weighing 2940 g (50th centile). She had a splint applied for congenital dislocation of the left hip. Her motor skills were at the extreme of the normal range but she was noted to be clumsy. She was unable to ride a bicycle until 8 years old. Speech and language development was delayed requiring speech therapy. She is educated in a mainstream school with extra help. Her height follows the 95th centile, head circumference on the 50th, and her weight is on the 25th. Upper to lower segment ratio is 0.85, arm span is less than height, and joint flexibility is normal. Her face is elongated, the nose is bulbous with a broad bridge, and the palate is high and arched. Her palpebral fissures are of normal length (3.1/2.9 cm). She has arachnodactyly with finger length on the 97th centile (8.6 cm), palm length 75th centile (10.5 cm), and middle finger to total hand ratio 45%. Her feet (fig 2) are narrow with an exaggerated arch and there is partial 2/3 syndactyly on the right and overriding 1st/2nd and 4th/5th toes on the left. Ophthalmological examination, echocardiography, and audiology are normal.

There is one older male sib who is developmentally normal. His height (aged 17) is 194 cm (>97th centile). In contrast to his sibs, he is of stocky build. Middle finger length is 9.6 cm and palm 11.9 cm. Middle finger to whole hand ratio is 44%. His karyotype is unknown. Three other pregnancies ended in early miscarriage at 12-14 weeks.

Maternal height is 169 cm (75th centile), middle finger length 7.2 cm, and palm length 10.5 cm, and the father's height is 180 cm (75th centile), middle finger length 8.8 cm, and palm length 12.3 cm. They are unrelated.

Cytogenetic studies using G banding showed an unbalanced translocation 46,XY or 46,XX,−10,+der(10)t(2;10)(p25.1;q26.3)mat resulting in distal 2p trisomy (2p+). Fluorescence in situ hybridisation studies were not performed as the same translocation in balanced form was identified in their mother and maternal grandmother. They are phenotypically normal. Previous descriptions of 2p+ have included skeletal abnormalities, facial dysmorphism, severe developmental delay, and cardiac and genital abnormalities. These features have been reported with break-
points at 2p21,1 2p22,2 and 2p23,3 usually in combination with partial monosomy involving one of various other chromosomes. However, with the exception of the report from Wakita et al, the breakpoint in this case differs from other published cases in that a much shorter duplicated segment is produced (fig 4). The reciprocal chromosome in the translocation also varies. In the case described by Wakita et al,4 trisomy 2p resulted from an isolated duplication 2p and not a translocation. In this case the 10qter deletion is very small (on G banding) and probably does not contribute to the phenotype, although modification of clinical expression by this deletion cannot be excluded.

In these two sibs, the translocation is inherited maternally. In other cases reported, paternal1 and maternal1 transmission as well as de novo1 duplications have been described with features consistent with distal trisomy 2p, making the role of imprinting less likely.

To our knowledge correlation of phenotype to duplicated segment length has not been possible. As this sib pair display some phenotypic differences from other cases described, they may contribute to the understanding of this correlation. The main phenotypic differences are summarised in table 1. In particular, these sibs have neither cardiac nor genital abnormalities and their development is mildly to moderately delayed. They do not have growth failure but have a marfanoid habitus. Arachnodactyly is a feature of Marfan syndrome which is associated with mutations in fibrillin genes mapped to chromosomes 5 and 15.5 However, the marfanoid habitus with mental retardation has also been described in an X linked disorder.6 Marfan-like cardiovascular and skeletal phenotype not linked to known fibrillin genes. Ann Hum Genet 1992;51:A183.

A combination of retardation (particularly speech and language) with arachnodactyly can also occur in 22q11 microdeletion syndrome, but these children have none of the associated features.7

The presence of arachnodactyly coupled with the evident marfanoid body is in the short duplication reported by Wakita et al leads us to conclude that this a key feature of duplications in this region. The influence of the reciprocal chromosome involved in the translocation must be considered. In other cases described,1–5 8 the reciprocal chromosome varies yet arachnodactyly is a constant feature. In this case, the 10qter deletion is unlikely to contribute much to the phenotype (although cannot be excluded) and the case reported by Wakita et al was an isolated duplication without a translocation, so the features described can be assumed to result from duplication of this region alone.

The common features evident in these children combined with the notable absence of others described in distal trisomy 2p syndrome aid the phenotype/genotype correlation in this region. We would be interested in other reports of duplications which would help this process.

Table 1 Comparison of features

<table>
<thead>
<tr>
<th>Feature</th>
<th>Female</th>
<th>Male</th>
<th>Others</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arachnodactyly</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pectus excavatum</td>
<td>−</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Developmental delay</td>
<td>Mild</td>
<td>Moderate</td>
<td>Severe</td>
</tr>
<tr>
<td>Postnatal growth delay</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Triangular face</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Bulbous nose</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>High arched palate</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Bossed forehead</td>
<td>−</td>
<td>+/*</td>
<td>+</td>
</tr>
<tr>
<td>Kyphoscoliosis</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Myopia</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Genital abnormalities</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Cardiac abnormalities</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
<tr>
<td>Fits</td>
<td>−</td>
<td>−</td>
<td>+</td>
</tr>
</tbody>
</table>